

# CITATION REPORT

List of articles citing

**Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer**

**DOI: 10.1093/jnci/djp082**

**Journal of the National Cancer Institute, 2009, 101, 736-50.**

**Source:** <https://exaly.com/paper-pdf/46896714/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1703	Relationship of CK8/18 expression pattern to breast cancer immunohistochemical subtyping in Egyptian patients. <b>2014</b> , 8, 404		3
1702	Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 1730; author reply 1730-1	9.7	9
1701	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. <b>2009</b> , 9, 433		141
1700	ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. <b>2009</b> , 1796, 162-75		79
1699	Expression of prostate apoptosis response (Par-4) is associated with progesterone receptor in breast cancer. <b>2009</b> , 40, 595-9		18
1698	Advances in endocrine therapy and its implications for translational research. <b>2009</b> , 1, 207-215		
1697	Breast cancer subtypes and molecular biomarkers. <b>2009</b> , 15, 485-489		7
1696	NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. <b>2009</b> , 7 Suppl 6, S1-S21; quiz S22-3		87
1695	Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. <b>2009</b> , 21, 491-8		3
1694	Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. <b>2010</b> , 1, 747-754		98
1693	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. <b>2010</b> , 4, 117822341000400		130
1692	Challenges in Developing New Biomarkers for Breast Cancer: Reply. <b>2010</b> , 34, 2792-2793		
1691	Breast Cancer Classification to Select Patients for Cancer Treatment. <b>2010</b> , 2, 152-158		
1690	Breast cancer, neoadjuvant chemotherapy and residual disease. <b>2010</b> , 12, 461-7		14
1689	A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (2010, 119, 653-61		56
1688	Combinatorial biomarker expression in breast cancer. <b>2010</b> , 120, 293-308		150
1687	Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. <b>2010</b> , 124, 607-17		150

1686	The androgen receptor in breast cancer: learning from the past. <b>2010</b> , 124, 619-21	12
1685	Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. <b>2010</b> , 123, 177-87	40
1684	Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. <b>2010</b> , 124, 689-99	55
1683	Histologic diagnosis in young women with breast cancer. <b>2010</b> , 123 Suppl 1, 15-8	3
1682	Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. <b>2010</b> , 124, 387-91	26
1681	Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. <b>2010</b> , 10, 294-300	89
1680	Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study. <b>2010</b> , 10, 223	50
1679	Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: a pathological and immunohistochemical study. <b>2010</b> , 19, 137-41	16
1678	Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. <b>2010</b> , 126, 1761-9	29
1677	A simple and economical method for the manual construction of frozen tissue arrays. <b>2010</b> , 118, 739-43	2
1676	Igf-Ii Mrna Expression in Breast Cancer: Predictive Value and Relationship to Other Prognostic Factors. <b>2010</b> , 25, 150-156	7
1675	Reinventing diagnostics for personalized therapy in oncology. <b>2010</b> , 2, 1066-91	3
1674	Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. <b>2010</b> , 4, 1-11	22
1673	Comparative validation of the SP6 antibody to Ki67 in breast cancer. <b>2010</b> , 63, 800-4	51
1672	Response: Re: Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 276-277	2
1671	Will molecular classification replace traditional breast pathology?. <b>2010</b> , 18, 162S-166S	15
1670	Breast cancer subtypes and the risk of local and regional relapse. <b>2010</b> , 28, 1684-91	903
1669	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. <b>2010</b> , 16, 5222-32	546

1668	Molecular stratification of triple-negative breast cancers. <b>2010</b> , 15 Suppl 5, 39-48	173
1667	Simultaneous targeting of estrogen receptor and HER2 in breast cancer. <b>2010</b> , 10, 1255-63	12
1666	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (. <b>2010</b> , 21, 1974-1981	161
1665	FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. <b>2010</b> , 70, 2085-94	533
1664	BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. <b>2010</b> , 16, 3988-97	32
1663	Re: Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 275-6; author reply 276-7	8
1662	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. <b>2010</b> , 7, e1000279	616
1661	Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH). <b>2010</b> , 34, 1180-5	27
1660	Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. <b>2010</b> , 79, 324-30	50
1659	Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. <b>2010</b> , 79, 255-61	21
1658	Loss of ER $\alpha$ and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. <b>2010</b> , 24, 1233-9	19
1657	[Hereditary breast cancer: the pathologist's point of view]. <b>2010</b> , 30, 90-2	
1656	DNA amplifications in breast cancer: genotypic-phenotypic correlations. <b>2010</b> , 6, 967-84	18
1655	Expresi3n de p63 y citoqueratina 5/6 en los diferentes tipos moleculares del carcinoma de mama. <b>2010</b> , 43, 79-85	
1654	Molecular basis for therapy resistance. <b>2010</b> , 4, 284-300	36
1653	Tumor size and survival in breast cancer--a reappraisal. <b>2010</b> , 7, 348-53	82
1652	Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. <b>2010</b> , 5, 18	23
1651	DNA methylation epigenotypes in breast cancer molecular subtypes. <b>2010</b> , 12, R77	141

1650	A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. <b>2010</b> , 12, R85	140
1649	Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. <b>2010</b> , 10, 188-95	32
1648	Prediction of benefit from adjuvant treatment in patients with breast cancer. <b>2010</b> , 10 Suppl 1, E32-7	6
1647	Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. <b>2010</b> , 23 Suppl 2, S60-4	241
1646	Personalized treatment of early-stage breast cancer: present concepts and future directions. <b>2010</b> , 36, 584-94	40
1645	Immunity to Trop-1, a newly identified breast cancer antigen, inhibits the growth of breast cancer in mice. <b>2010</b> , 28, 7757-63	1
1644	Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. <b>2010</b> , 176, 2139-49	36
1643	Breast cancer assessment tools and optimizing adjuvant therapy. <b>2010</b> , 7, 725-32	75
1642	Ki67 in breast cancer: prognostic and predictive potential. <b>2010</b> , 11, 174-83	739
1641	The Met oncogene and basal-like breast cancer: another culprit to watch out for?. <b>2010</b> , 12, 208	56
1640	Metastatic behavior of breast cancer subtypes. <b>2010</b> , 28, 3271-7	1300
1639	Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer. <b>2011</b> , 13,	78
1638	Molecular classification of triple-negative tumors. <b>2011</b> , 13,	78
1637	Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?. <b>2011</b> , 13,	78
1636	Epithelial-mesenchymal transition as a mechanism for the progression of breast carcinoma. <b>2011</b> , 13,	1
1635	Epigenetics of breast cancer. <b>2011</b> , 13,	78
1634	Immunity and autoimmunity in breast cancer. <b>2011</b> , 13,	78
1633	Insulin resistance in breast cancer: relevance and clinical implications. <b>2011</b> , 13,	1

1632	The phosphatidylinositol-3 kinase/mTOR pathway: new agents. <b>2011, 13,</b>	1
1631	DNA repair and breast cancer: therapeutic opportunities. <b>2011, 13,</b>	78
1630	NoncodingRNAs: from bench to bedside. <b>2011, 13,</b>	78
1629	Targeting HER2 in breast cancer: beyond trastuzumab. <b>2011, 13,</b>	78
1628	Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer. <b>2011, 13,</b>	78
1627	Molecular heterogeneity of luminal breast cancer. <b>2011, 13,</b>	78
1626	Translational breast cancer research in luminal breast cancer. <b>2011, 13,</b>	78
1625	Interpretation and molecular validation of biomarker studies. <b>2011, 13,</b>	1
1624	Clinical features and prognosis of tubular breast cancer. <b>2011, 13,</b>	78
1623	Abstract withdrawn. <b>2011, 13,</b>	78
1622	Nestin and collagen triple helix repeat containing 1 in breast cancer progression. <b>2011, 13,</b>	78
1621	Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy. <b>2011, 13,</b>	78
1620	Oestrogen receptor status predicts for local recurrence following wide local excision for breast tumours. <b>2011, 13,</b>	1
1619	Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value. <b>2011, 13,</b>	78
1618	Lobular carcinoma of the breast: outcome of 205 patients. <b>2011, 13,</b>	78
1617	BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients. <b>2011, 13,</b>	1
1616	Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin. <b>2011, 13,</b>	1
1615	microRNA and protein expression in breast cancer formalin-fixed paraffin-embedded samples. <b>2011, 13,</b>	78

1614	Quantitative proteomics reveals novel proteins and central pathways associated with endocrine resistance in breast cancer. <b>2011</b> , 13,		78
1613	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. <b>2011</b> , 13,		78
1612	Expression patterns of ER, HER2, and NM23-H1 in breast cancer patients with different menopausal status: correlations with metastasis. <b>2011</b> , 15, 211-9		7
1611	Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. <b>2011</b> , 105, 272-80		48
1610	Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. <b>2011</b> , 11, 813-27		33
1609	Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 1656-64	9.7	1156
1608	[Proliferation evaluation by measuring Ki67 in breast neoplasms]. <b>2011</b> , 31, S57-9		1
1607	Micrometastatic Node-Positive Breast Cancer: Long-Term Outcomes and Identification of High-Risk Subsets in a Large Population-Based Series: Truong PT, Lesperance M, Li KH, et al (British Columbia Cancer Agency, Victoria, Canada; Univ of Victoria, British Columbia, Canada; et al) <i>Ann Surg Oncol</i> 17:2122-2131, 2010. <b>2011</b> , 22, 51-59		
1606	Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer?: Falck A-K, FernØM, Bendahl P-O, et al (Lund Univ Hosp, Sweden) <i>World J Surg</i> 34:1434-1441, 2010. <b>2011</b> , 22, 50-51		
1605	Breast. <b>2011</b> , 225-247		1
1604	Deconstructing the molecular portraits of breast cancer. <b>2011</b> , 5, 5-23		841
1603	Tailoring therapy for locally advanced breast cancer using molecular profiles: are we there yet?. <b>2011</b> , 71, 1947-55		0
1602	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. <b>2011</b> , 11, 486		211
1601	Handbook of Practical Immunohistochemistry. <b>2011</b> ,		5
1600	Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. <b>2011</b> , 71, 3364-76		563
1599	Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. <b>2011</b> , 47, 1779-88		19
1598	Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. <b>2011</b> , 64, 937-46		383
1597	Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. <b>2011</b> , 22, 1736-47		2402

1596	Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. <b>2011</b> , 42, 153-65	5
1595	Molecular phenotypes of matched in situ and invasive components of breast carcinomas. <b>2011</b> , 42, 1438-46	8
1594	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <b>2011</b> , 12, 1134-42	141
1593	[Hormone therapy and breast cancer]. <b>2011</b> , 98, 1311-9	7
1592	Implications of genomic instability in the diagnosis and treatment of breast cancer. <b>2011</b> , 11, 445-53	26
1591	Luminal-B breast cancer and novel therapeutic targets. <b>2011</b> , 13, 221	142
1590	Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression. <b>2011</b> , 13, R95	19
1589	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. <b>2011</b> , 13, R109	18
1588	Challenges to developing proteomic-based breast cancer diagnostics. <b>2011</b> , 15, 251-9	18
1587	CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. <b>2011</b> , 6, 638-49	82
1586	Imaging-related anatomy and pathology. 22-47	
1585	Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics. <b>2011</b> , 58, 189-97	14
1584	MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. <b>2010</b> , 8, 53-60	20
1583	Ki67 expression in oestrogen receptor positive breast ductal carcinoma. <b>2011</b> , 43, S60	
1582	Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer. <b>2012</b> , 27, 28-38	36
1581	Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. <b>2011</b> , 22, 2201-7	69
1580	Detection of sepsis in neonate using neutrophil VCS parameters on beckman coulter LH750 haematology analyser (method introduction and optimisation in haematology laboratory at royal north shore hospital). <b>2011</b> , 43, S60	
1579	Massive gastric dilatation and sudden death. <b>2011</b> , 43, S71	



1578 Ki67 expression in oestrogen receptor positive breast ductal carcinoma. **2011**, 43, S70-S71

1577 Ruptured appendiceal diverticula. **2011**, 43, S71

1

1576 A collision tumour of the oesophagus. **2011**, 43, S71

1575 Board of Education Trainee Poster Prize. **2011**, 43, S60-S67

1574 General Poster Display. **2011**, 43, S70-S84

1573 Characteristics of breast cancers detected by ultrasound screening in women with negative mammograms. **2011**, 102, 1862-7

37

1572 Protective effects of green tea on intestinal ischemia-reperfusion injury. **2011**, 27, 598-603

14

1571 Adjuvant chemotherapy in luminal breast cancers. **2011**, 20 Suppl 3, S128-31

13

1570 Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6EEC versus 3EEC/3Docetaxel. **2011**, 11, 140

37

1569 Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. **2011**, 11, 292

80

1568 Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients. **2011**, 6, 57

6

1567 Metastatic triple-negative breast cancer. **2011**, 23, 587-600

81

1566 Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study. **2011**, 11, 332-41

19

1565 Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. **2011**, 18, 2885-92

8

1564 Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. **2011**, 50, 700-10

186

1563 DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer. **2011**, 127, 53-63

48

1562 MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. **2011**, 127, 591-9

82

1561 Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation. **2011**, 129, 373-86

22

1560	MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. <b>2011</b> , 130, 735-45	105
1559	Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. <b>2011</b> , 127, 133-42	149
1558	Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter?. <b>2011</b> , 129, 211-9	8
1557	Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. <b>2011</b> , 128, 127-36	61
1556	Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. <b>2011</b> , 127, 713-20	85
1555	Struggling with subtypes: trying to bridge the gap between molecular breast cancer subtypes and clinical management. <b>2011</b> , 130, 421-3	0
1554	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. <b>2011</b> , 128, 447-56	149
1553	Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. <b>2011</b> , 128, 783-94	217
1552	CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. <b>2011</b> , 130, 645-55	214
1551	Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. <b>2011</b> , 129, 867-75	40
1550	A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. <b>2011</b> , 130, 489-98	66
1549	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. <b>2011</b> , 130, 477-87	143
1548	Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases--elevated Bmi-1 expression in late breast cancer relapses. <b>2011</b> , 459, 31-9	33
1547	Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. <b>2011</b> , 17, 753-8	36
1546	Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. <b>2011</b> , 11, 44	38
1545	ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. <b>2011</b> , 3, 153-66	88
1544	High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. <b>2011</b> , 129, 536-45	37
1543	Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis. <b>2011</b> , 77, 20-9	44

1542	P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. <b>2011</b> , 24, 64-81	50
1541	The changing role of pathology in breast cancer diagnosis and treatment. <b>2011</b> , 78, 99-114	77
1540	Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. <b>2011</b> , 24, 924-31	207
1539	Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. <b>2011</b> , 22, 1770-6	25
1538	Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. <b>2011</b> , 29, 3885-91	299
1537	Invasive Breast Cancer: Recognition of Molecular Subtypes. <b>2011</b> , 6, 258-264	25
1536	Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 1363-72	9.7 40
1535	Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. <b>2011</b> , 17, 7828-34	12
1534	A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy. <b>2011</b> , 2011, 217060	15
1533	Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. <b>2011</b> , 4, 1609-16	15
1532	Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. <b>2011</b> , 18, 721-30	6
1531	Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. <b>2011</b> , 16, 1675-83	70
1530	Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer. <b>2011</b> , 6, 193-198	5
1529	Molecular classification of breast cancer: is it time to pack up our microscopes?. <b>2011</b> , 43, 1-8	20
1528	Molecular stratification of triple-negative breast cancers. <b>2011</b> , 16 Suppl 1, 61-70	247
1527	A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. <b>2011</b> , 17, 2024-34	75
1526	Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. <b>2011</b> , 17, 2874-84	93
1525	Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?. <b>2011</b> , 8, 272-9	25

1524	gef gene expression in MCF-7 breast cancer cells is associated with a better prognosis and induction of apoptosis by p53-mediated signaling pathway. <b>2011</b> , 12, 7445-58	5
1523	Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients. <b>2011</b> , 29, 180-6	3
1522	Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer. <b>2011</b> , 80, 341-9	11
1521	Breast cancer subtypes and outcome after local and regional relapse. <b>2012</b> , 23, 324-31	48
1520	Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. <b>2012</b> , 23, 1422-7	53
1519	Molecular subtyping of male breast cancer by immunohistochemistry. <b>2012</b> , 25, 398-404	101
1518	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. <b>2012</b> , 23, 2578-2584	40
1517	Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. <b>2012</b> , 23 Suppl 10, x219-27	46
1516	Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. <b>2012</b> , 1, 1104-1110	48
1515	Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. <b>2012</b> , 17, 1418-25	35
1514	Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. <b>2012</b> , 23, 2866-2873	103
1513	Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX <sup>®</sup> ) and the PAM50 breast cancer intrinsic Classifier <sup>®</sup> in early-stage estrogen receptor-positive breast cancer. <b>2012</b> , 17, 492-8	63
1512	Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. <b>2012</b> , 97, 1745-51	92
1511	Molecular classification of estrogen receptor-positive/luminal breast cancers. <b>2012</b> , 19, 39-53	53
1510	Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer. <b>2012</b> , 51, 386-93	30
1509	A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. <b>2012</b> , 18, 4465-72	215
1508	Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. <b>2012</b> , 83, 228-33	11
1507	Target-based anti-angiogenic therapy in breast cancer. <b>2012</b> , 18, 4244-57	32

1506	Prognose beim Mammakarzinom. <b>2012</b> , 44, 17-25	1
1505	Systemische Therapie des Mammakarzinoms - State of the Art. <b>2012</b> , 41, 146-149	
1504	Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. <b>2012</b> , 23, 1138-1144	16
1503	Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. <b>2012</b> , 18, 2402-12	117
1502	Biomarkers in Breast Cancer - An Update. <b>2012</b> , 72, 819-832	25
1501	[Modern pharmacological therapy of breast cancer]. <b>2012</b> , 153, 56-65	2
1500	Reappraisal of immunohistochemical profiling of special histological types of breast carcinomas: a study of 121 cases of eight different subtypes. <b>2012</b> , 65, 1066-71	15
1499	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. <b>2012</b> , 209, 679-96	252
1498	Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. <b>2012</b> , 4, 127-37	22
1497	Targeting abnormal DNA repair in therapy-resistant breast cancers. <b>2012</b> , 10, 96-107	62
1496	Marqueurs pronostiques et prédictifs des cancers du sein précoces. <b>2012</b> , 41-49	
1495	Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. <b>2012</b> , 6, 1-8	43
1494	Is adjuvant chemotherapy useful for women with luminal a breast cancer?. <b>2012</b> , 30, 1260-3	49
1493	Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. <b>2012</b> , 9, 223-9	34
1492	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. <b>2012</b> , 23, 2997-3006	189
1491	Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. <b>2012</b> , 103, 129-45	27
1490	Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone 1 and 11 to overcome tamoxifen resistance in breast cancer cells. <b>2012</b> , 41, 1845-54	26
1489	Proteomic classification of breast cancer. <b>2012</b> , 13, 1495-509	15

1488	Imaging as a potential tool for subtyping breast cancer. <b>2012</b> , 4, 577-579	
1487	Association between body mass index and breast cancer intrinsic subtypes in Japanese women. <b>2012</b> , 4, 391-396	5
1486	Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. <b>2012</b> , 58, 532-536	3
1485	Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. <b>2012</b> , 38, 698-707	342
1484	Molecular pathology of breast cancer: what a pathologist needs to know. <b>2012</b> , 138, 770-80	66
1483	Immunophenotyping of male breast cancer. <b>2012</b> , 61, 1145-55	25
1482	Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. <b>2012</b> , 6, 494-506	114
1481	Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients. <b>2012</b> , 135, 459-67	40
1480	Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy. <b>2012</b> , 30, 663-78	15
1479	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <b>2012</b> , 13, e240-8	51
1478	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. <b>2012</b> , 14, R70	47
1477	Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. <b>2012</b> , 14, R95	80
1476	The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. <b>2012</b> , 14, R113	36
1475	Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. <b>2012</b> , 14, R143	43
1474	Prolifération et signatures ADN de complexité génomique pour la définition du pronostic des carcinomes mammaires. <b>2012</b> , 14, 502-505	
1473	Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours. <b>2012</b> , 134, 1005-11	5
1472	Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. <b>2012</b> , 135, 885-92	30
1471	Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. <b>2012</b> , 136, 153-60	81

1470	Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. <b>2012</b> , 12, 340-6	37
1469	Breast conservation therapy: the influence of molecular subtype and margins. <b>2012</b> , 83, 814-20	21
1468	Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. <b>2012</b> , 58, 532-536	16
1467	Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?. <b>2012</b> , 84 Suppl 1, e58-69	10
1466	Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. <b>2012</b> , 58, 532-536	1
1465	Outcome of special types of luminal breast cancer. <b>2012</b> , 23, 1428-36	79
1464	Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients. <b>2012</b> , 19, 3755-61	15
1463	Comparison of molecular subtyping with Blueprint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. <b>2012</b> , 19, 3257-63	33
1462	Progranulin expression in breast cancer with different intrinsic subtypes. <b>2012</b> , 208, 210-6	14
1461	Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo. <b>2012</b> , 50, 1632-41	24
1460	New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. <b>2012</b> , 38, 303-10	24
1459	Positive or close margins in breast conserving surgery: is re-excision always necessary?. <b>2012</b> , 38, 399-406	20
1458	Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis. <b>2012</b> , 12, 106	22
1457	Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. <b>2012</b> , 12, 216	6
1456	Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. <b>2012</b> , 12, 74	33
1455	A pure invasive cribriform carcinoma of the breast with bone metastasis if untreated for thirteen years: a case report and literature review. <b>2012</b> , 10, 251	10
1454	Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. <b>2012</b> , 10, 212	28
1453	Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. <b>2012</b> , 5, 376	59

1452	Targeting the subtypes of breast cancer: rethinking investigational drugs. <b>2012</b> , 21, 191-204	1
1451	Biomarkers in the diagnosis of primary and recurrent breast cancer. <b>2012</b> , 6, 567-85	20
1450	Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. <b>2012</b> , 106, 1798-806	56
1449	Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. <b>2012</b> , 73, 998-1004	28
1448	Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. <b>2012</b> , 107, 382-7	67
1447	Practical implications of gene-expression-based assays for breast oncologists. <b>2011</b> , 9, 48-57	205
1446	Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. <b>2012</b> , 9, 529-41	57
1445	Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. <b>2012</b> , 29, 1536-42	13
1444	Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. <b>2012</b> , 29, 3222-31	15
1443	[Translational research and diagnostics for breast cancer]. <b>2012</b> , 33 Suppl 2, 282-90	5
1442	High-risk estrogen-receptor-positive breast cancer: identification and implications for therapy. <b>2012</b> , 16, 235-40	3
1441	Strategy for SRM-based verification of biomarker candidates discovered by iTRAQ method in limited breast cancer tissue samples. <b>2012</b> , 11, 4201-10	58
1440	CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. <b>2012</b> , 14, R48	290
1439	Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study. <b>2012</b> , 7, e35198	22
1438	Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. <b>2012</b> , 7, e37946	49
1437	Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers. <b>2012</b> , 7, e38575	24
1436	Invasive neuroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients. <b>2013</b> , 60, 215-22	36
1435	The molecular profile of luminal B breast cancer. <b>2012</b> , 6, 289-97	116



1434	Outcome Evaluation in Pre-Trastuzumab Era between Different Breast Cancer Phenotypes: A Population-Based Study on Italian Women. <b>2012</b> , 98, 743-750	9
1433	Analysis of the potent prognostic factors in luminal-type breast cancer. <b>2012</b> , 15, 401-6	21
1432	Assessing the clinical significance of tumor markers in common neoplasms. <b>2012</b> , 4, 2558-78	8
1431	HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. <b>2012</b> , 10, 10	40
1430	Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?. <b>2012</b> , 14, 104	1
1429	A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. <b>2012</b> , 226, 97-107	61
1428	Prognostic value of basal phenotype in HER2-overexpressing breast cancer. <b>2012</b> , 19, 935-40	23
1427	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <b>2012</b> , 18, 1052-9	177
1426	Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. <b>2012</b> , 23, 3069-3074	123
1425	Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. <b>2012</b> , 23, 338-45	57
1424	AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. <b>2012</b> , 134, 671-81	19
1423	Behaviour of breast cancer molecular subtypes through tumour progression. <b>2012</b> , 14, 481-5	12
1422	Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. <b>2012</b> , 19, 218-37	70
1421	Correlations between diffusion-weighted imaging and breast cancer biomarkers. <b>2012</b> , 22, 1519-28	164
1420	Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. <b>2012</b> , 132, 937-45	27
1419	A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. <b>2012</b> , 133, 37-47	88
1418	Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. <b>2012</b> , 132, 895-915	216
1417	A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. <b>2012</b> , 133, 949-58	97

1416	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <b>2012</b> , 132, 1049-62	252
1415	Invasive lobular breast cancer: subtypes and outcome. <b>2012</b> , 133, 713-23	94
1414	A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. <b>2012</b> , 60, 854-63	18
1413	Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. <b>2012</b> , 21, 50-7	141
1412	Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. <b>2012</b> , 21, 336-42	9
1411	Her2 negative luminal breast carcinoma and Ki-67 evaluation. <b>2012</b> , 21, 529-33	6
1410	Implementation of TMA and digitalization in routine diagnostics of breast pathology. <b>2012</b> , 120, 341-7	12
1409	Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. <b>2012</b> , 103, 1508-12	39
1408	Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. <b>2012</b> , 103, 1679-87	41
1407	Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. <b>2012</b> , 14, R3	94
1406	Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. <b>2012</b> , 19, 1145-52	39
1405	Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. <b>2012</b> , 118, 17-26	49
1404	Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. <b>2012</b> , 118, 914-23	12
1403	Tools der Pathologie zur Umsetzung genetischer Erkenntnisse. <b>2012</b> , 45, 23-27	
1402	Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. <b>2012</b> , 69, 533-46	21
1401	FOXA1 is an independent prognostic marker for ER-positive breast cancer. <b>2012</b> , 131, 881-90	92
1400	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. <b>2012</b> , 132, 131-42	91
1399	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. <b>2012</b> , 131, 159-67	146

1398	Prognostic role of CA15.3 in 7942 patients with operable breast cancer. <b>2012</b> , 132, 317-26	20
1397	Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. <b>2012</b> , 131, 1061-6	176
1396	Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. <b>2013</b> , 11, 129	72
1395	Illuminating luminal B: QSOX1 as a subtype-specific biomarker. <b>2013</b> , 15, 104	12
1394	A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis. <b>2013</b> , 34, 1263-71	14
1393	Relative and disease-free survival for breast cancer in relation to subtype: a population-based study. <b>2013</b> , 139, 1569-77	28
1392	Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. <b>2013</b> , 20, 262-70	32
1391	Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas. <b>2013</b> , 209, 296-301	15
1390	A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. <b>2013</b> , 26, 1438-50	47
1389	Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors. <b>2013</b> , 139, 1637-47	10
1388	CX3CL1 expression is associated with poor outcome in breast cancer patients. <b>2013</b> , 140, 495-504	35
1387	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) trials. <b>2013</b> , 13, 163	24
1386	The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer. <b>2013</b> , 13, 42	18
1385	Klinische und morphologische Parameter beim Mammakarzinom. <b>2013</b> , 46, 369-376	
1384	Prädiktion beim Mammakarzinom. <b>2013</b> , 46, 377-381	1
1383	A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. <b>2013</b> , 13, 5	29
1382	Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. <b>2013</b> , 13, 1	17
1381	A new genome-driven integrated classification of breast cancer and its implications. <b>2013</b> , 32, 617-28	212

1380	Low expression of Beclin 1 and elevated expression of HIF-1 $\beta$ refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer. <b>2013</b> , 30, 355	35
1379	Prognostic value of immunohistochemical stratification of invasive duct carcinoma of the breast. <b>2013</b> , 12, 265-272	2
1378	Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. <b>2013</b> , 140, 63-71	67
1377	Array Comparative Genomic Hybridization. <b>2013</b> ,	1
1376	Imaging features of sporadic breast cancer in women under 40 years old: 97 cases. <b>2013</b> , 23, 3237-45	23
1375	Molecular subtypes of breast cancer: metabolic correlation with $^{18}$ F-FDG PET/CT. <b>2013</b> , 40, 1304-11	52
1374	Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. <b>2013</b> , 71, 245-55	38
1373	Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. <b>2013</b> , 119, 1960-8	42
1372	Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. <b>2013</b> , 32, 4120-9	30
1371	Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?. <b>2013</b> , 39, 1358-63	28
1370	MicroRNA signatures in hereditary breast cancer. <b>2013</b> , 142, 19-30	28
1369	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <b>2013</b> , 24, 2206-23	2048
1368	Breast carcinoma: molecular profiling and updates. <b>2013</b> , 33, 891-909	4
1367	The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value. <b>2013</b> , 13, 146-52	17
1366	Pan-cancer patterns of somatic copy number alteration. <b>2013</b> , 45, 1134-40	1198
1365	Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis. <b>2013</b> , 22, 879-86	31
1364	High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy. <b>2013</b> , 49, 3083-92	11
1363	Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. <b>2013</b> , 183, 1113-1124	157

1362	Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade. <b>2013</b> , 141, 231-42	22
1361	Three molecular classifications surrogate to four immunohistochemical markers in 374 invasive breast carcinomas with long follow-up: which is better?. <b>2013</b> , 209, 337-44	1
1360	BRCAness: a deeper insight into basal-like breast tumors. <b>2013</b> , 24 Suppl 8, viii13-viii21	47
1359	Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence. <b>2013</b> , 20, 1886-92	16
1358	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. <b>2013</b> , 138, 899-908	18
1357	Prolifation des cancers du sein et biomarqueurs d'cisionnels en pratique RPC (RPC 2013). <b>2013</b> , 15, 594-604	2
1356	Cancers du sein T1a,b N0 M0 (RPC 2013). <b>2013</b> , 15, 637-670	4
1355	Les traitements n'adjuvants TNA (RPC 2013). <b>2013</b> , 15, 607-634	2
1354	Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. <b>2013</b> , 30, 700	44
1353	Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers. <b>2013</b> , 142, 311-22	17
1352	Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. <b>2013</b> , 142, 237-55	132
1351	Tailoring adjuvant treatments for the individual patient with luminal breast cancer. <b>2013</b> , 27, 703-14, vii-viii	5
1350	Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss. <b>2013</b> , 26, 1161-71	35
1349	The role of core biopsy in the preoperative classification of breast cancer according to prognostic factors. <b>2013</b> , 85, 1-7	
1348	Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype. <b>2013</b> , 20, 1505-13	26
1347	The classification of invasive carcinoma of the breast. <b>2013</b> , 13, 941-54	9
1346	The genomic map of breast cancer: which roads lead to better targeted therapies?. <b>2013</b> , 15, 209	10
1345	Ki67 and proliferation in breast cancer. <b>2013</b> , 66, 512-6	139

1344 Breast Cancer. **2013**, 707-713

1343	Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer. <b>2013</b> , 52, 82-90	13
1342	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. <b>2013</b> , 31, 203-9	376
1341	Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. <b>2013</b> , 139, 269-80	16
1340	Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. <b>2013</b> , 24, 661-8	81
1339	Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. <b>2013</b> , 51, 439-47	23
1338	Outcome in breast molecular subtypes according to nodal status and surgical procedures. <b>2013</b> , 205, 662-7	34
1337	Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer. <b>2013</b> , 185, 697-703	29
1336	The continued evidence from overviews: what is the clinical utility?. <b>2013</b> , 22 Suppl 2, S8-11	1
1335	Role of Ki67 in predicting resistance to adjuvant tamoxifen in postmenopausal breast cancer patients. <b>2013</b> , 25, 181-91	9
1334	One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. <b>2013</b> , 49, 2986-94	5
1333	Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. <b>2013</b> , 25, 109-16	33
1332	Molecular pathways and molecular imaging in breast cancer: an update. <b>2013</b> , 40, 581-91	11
1331	The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature. <b>2013</b> , 29, 1453-61	14
1330	Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. <b>2013</b> , 182, 2037-47	42
1329	Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. <b>2013</b> , 130, 609-14	45
1328	Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"?. <b>2013</b> , 22, 1046-51	23
1327	The Ki-67/MIB-1 index level and recurrence of papillary thyroid carcinoma. <b>2013</b> , 80, 311-4	7

1326	Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype. <b>2013</b> , 44, 2487-93	13
1325	Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?. <b>2013</b> , 216, 239-51	46
1324	Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations. <b>2013</b> , 13, 119-28	16
1323	Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience. <b>2013</b> , 22, 419-24	11
1322	Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis. <b>2013</b> , 22, 643-9	3
1321	Nonfamilial breast cancer subtypes. <b>2013</b> , 973, 279-95	5
1320	Adjuvant systemic therapies in breast cancer. <b>2013</b> , 93, 473-91	43
1319	Biomarkers for the clinical management of breast cancer: international perspective. <b>2013</b> , 133, 1-13	118
1318	Chemotherapy regimens in early breast cancer: major controversies and future outlook. <b>2013</b> , 13, 165-78	16
1317	Comprehensive analysis of PTEN status in breast carcinomas. <b>2013</b> , 133, 323-34	36
1316	Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. <b>2013</b> , 23, 2420-31	73
1315	Role of microRNAs in breast cancer. <b>2013</b> , 14, 201-12	97
1314	Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. <b>2013</b> , 139, 539-52	346
1313	Molecular and clinicopathological markers of prognosis in breast cancer. <b>2013</b> , 13, 481-98	4
1312	Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. <b>2013</b> , 140, 93-104	41
1311	CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. <b>2013</b> , 133, 2398-407	81
1310	Immunohistochemically defined subtypes and outcome of apocrine breast cancer. <b>2013</b> , 13, 95-102	42
1309	Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: application and outcomes. <b>2013</b> , 22, 793-8	13

1308	The evolving landscape of protein kinases in breast cancer: clinical implications. <b>2013</b> , 39, 68-76	19
1307	St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. <b>2013</b> , 13, 558	32
1306	Shear-wave elastography of invasive breast cancer: correlation between quantitative mean elasticity value and immunohistochemical profile. <b>2013</b> , 138, 119-26	66
1305	Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. <b>2013</b> , 18, 343-9	11
1304	[Gene expression analysis in breast cancer. A new diagnostic tool in pathology]. <b>2013</b> , 34, 413-8	1
1303	Oncogenic PIK3CA mutations in lobular breast cancer progression. <b>2013</b> , 52, 69-80	27
1302	Overexpression of activated phospholipase C $\alpha$ 1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy. <b>2013</b> , 132, 1022-31	32
1301	An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications. <b>2013</b> , 80, 111-8	23
1300	Targeted approaches to triple-negative breast cancer: current practice and future directions. <b>2013</b> , 20, 605-12	15
1299	Aufgaben der Pathologie in der Begutachtung von Präparaten aus der Frauenheilkunde. <b>2013</b> , 73, R27-R46	
1298	Mammakarzinom 2013 [Interpretation neuer und bekannter Daten. <b>2013</b> , 10, 215-224	
1297	Prädiktive Biomarker beim ER+/HER2 - Mammakarzinom - Diskrepanz zwischen S3-Leitlinie, AGO-Empfehlung und St.-Gallen-Expertenmeinung. <b>2013</b> , 10, 34-38	
1296	Breast Cancer 2013 - Interpretation of New and Known Data. <b>2013</b> , 73, 584-598	6
1295	Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer. <b>2013</b> , 26, 79-86	18
1294	Are breast cancer molecular classes predictive of survival in patients with long follow-up?. <b>2013</b> , 35, 595-605	11
1293	Hormone receptor expression in breast cancer: postanalytical issues. <b>2013</b> , 66, 478-84	13
1292	Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer. <b>2012</b> , 34, 9-17	5
1291	Survival Analysis Based on Clinicopathological Data From a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy. <b>2013</b> , 2013, 606398	1



1290	Genomic grade adds prognostic value in invasive lobular carcinoma. <b>2013</b> , 24, 377-384		35
1289	Significance analysis of prognostic signatures. <b>2013</b> , 9, e1002875		22
1288	Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. <b>2013</b> , 24, 1203-11		18
1287	Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis. <b>2013</b> , 66, 649-54		14
1286	Ductal carcinoma in situ: morphology-based knowledge and molecular advances. <b>2013</b> , 20, 205-16		14
1285	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 960-7	9.7	112
1284	Molecular Classification and Prognostic Signatures of Breast Tumors. <b>2013</b> , 55-62		
1283	Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. <b>2013</b> , 22, 21-8		31
1282	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. <b>2013</b> , 24, 640-7		137
1281	From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis. <b>2013</b> , 2, 243-64		4
1280	ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. <b>2013</b> , 7, 23-34		44
1279	Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. <b>2013</b> , 52, 102-9		38
1278	Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. <b>2013</b> , 52, 91-101		18
1277	Treatment of estrogen receptor-positive breast cancer. <b>2013</b> , 20, 596-604		142
1276	Genomic profiling in luminal breast cancer. <b>2013</b> , 8, 414-22		10
1275	High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer. <b>2013</b> , 2, 437-46		33
1274	Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer. <b>2013</b> , 2, 763-73		14
1273	Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study. <b>2013</b> , 104, 1539-43		55

1272	HER-2/neu mediates oncogenic transformation via altered CREB expression and function. <b>2013</b> , 11, 1462-77	25
1271	Clinicopathological analysis of breast ductal carcinoma in situ with ALDH1-positive cancer stem cells. <b>2013</b> , 85, 248-56	9
1270	Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. <b>2013</b> , 108, 1593-601	29
1269	Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer. <b>2013</b> , 66, 291-6	13
1268	Estado del arte el diagnóstico y tratamiento del cáncer de mama. <b>2013</b> , 24, 588-609	
1267	Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. <b>2013</b> , 15, R98	69
1266	Hormone Receptors and Endocrine Therapy in Breast Cancer. <b>2013</b> , 121-153	
1265	Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. <b>2013</b> , 47, 57-62	2
1264	Control of Receptor Function by MicroRNAs in Breast Cancer. <b>2013</b> , 287-310	
1263	Molekulares Profil im Visier. <b>2013</b> , 18, 21-25	
1262	Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis. <b>2013</b> , 25, 112-8	1
1261	Low methylation levels of the SFRP1 gene are associated with the basal-like subtype of breast cancer. <b>2013</b> , 29, 1946-54	13
1260	The SUVmax for (18)F-FDG correlates with molecular subtype and survival of previously untreated metastatic breast cancer. <b>2013</b> , 38, 256-62	10
1259	Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer. <b>2013</b> , 1, 703-710	6
1258	Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors. <b>2013</b> , 16, 66-71	4
1257	Prognostic value of the nodal ratio and ki-67 expression in breast cancer patients treated with postmastectomy radiotherapy. <b>2013</b> , 16, 274-84	4
1256	Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women. <b>2013</b> , 9, 466-71	14
1255	Distribution of CXCR4 and E-catenin expression pattern in breast cancer subtypes and their relationship to axillary nodal involvement. <b>2013</b> , 64, 253-9	7

1254	Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. <b>2013</b> , 6, 839-52	70
1253	Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer. <b>2013</b> , 1, 93-99	6
1252	Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. <b>2013</b> , 8, e55901	25
1251	Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response. <b>2013</b> , 16, 395-403	20
1250	Neoadjuvant (Preoperative) Therapy in Breast Cancer. <b>2013</b> ,	
1249	Adjuvant chemotherapy: which patient? What regimen?. <b>2013</b> , 3-8	3
1248	Pathogenesis, prevention, diagnosis and treatment of breast cancer. <b>2014</b> , 5, 283-98	130
1247	Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. <b>2014</b> , 9, e88401	27
1246	Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. <b>2014</b> , 9, e87264	26
1245	A microRNA signature associated with early recurrence in breast cancer. <b>2014</b> , 9, e91884	64
1244	Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer. <b>2014</b> , 9, e98673	14
1243	The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFR $\beta$ closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. <b>2014</b> , 9, e102176	37
1242	Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17. <b>2014</b> , 9, e103707	3
1241	[18F]-fluorodeoxyglucose positron emission tomography can contribute to discriminate patients with poor prognosis in hormone receptor-positive breast cancer. <b>2014</b> , 9, e105905	14
1240	Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. <b>2014</b> , 9, e112121	41
1239	Positive Margins following Breast Cancer Tumorectomy. Can we Predict the Occurrence of Residual Disease?. <b>2014</b> , 100, 420-425	5
1238	Subtype is a predictive factor of nonsentinel lymph node involvement in sentinel node-positive breast cancer patients. <b>2014</b> , 17, 370-5	16
1237	Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast. <b>2014</b> , 17, 323-31	56

1236	Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. <b>2014</b> , 5, 633-45	6
1235	[The new classification of breast cancers: finding the luminal A]. <b>2014</b> , 36, 575-80	7
1234	The biological markers and results of treatment in male breast cancer patients. The Cracow experience. <b>2014</b> , 61, 331-9	2
1233	HER2-positive endometrial cancer subtype carries poor prognosis. <b>2014</b> , 7, 482-8	16
1232	Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil. <b>2014</b> , 14, 110	22
1231	Optimal adjuvant chemotherapy in breast cancer: selection of agents. <b>2014</b> , 7, 605-11	3
1230	Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer. <b>2014</b> , 203, 272-9	30
1229	Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer. <b>2014</b> , 14, 672	4
1228	Invasive Breast Carcinoma. <b>2014</b> , 934-951	3
1227	HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy. <b>2014</b> , 12, 289	18
1226	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. <b>2014</b> , 148, 511-23	23
1225	MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study. <b>2014</b> , 14, 739	37
1224	Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer. <b>2014</b> , 3, e118	24
1223	Successes and limitations of targeted cancer therapy in breast cancer. <b>2014</b> , 41, 15-35	23
1222	Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. <b>2014</b> , 8, 107-11	75
1221	Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast. <b>2014</b> , 7, 107-114	12
1220	Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). <b>2014</b> , 2, 41-52	70
1219	Gene Expression Profiles in Breast Cancer to Identify Estrogen Receptor Target Genes. <b>2014</b> , 381-403	

1218	Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. <b>2014</b> , 2014, 469251		128
1217	Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma. <b>2014</b> , 138, 175-81		8
1216	Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. <b>2014</b> , 53, 1337-46		28
1215	Distribution of podoplanin-positive tumor vessels predicts disease-specific survival of node-positive breast cancer patients treated with anthracyclines and/or taxanes. <b>2014</b> , 32, 168-77		2
1214	Predictive factors for response to neoadjuvant therapy in breast cancer. <b>2014</b> , 37, 563-8		17
1213	Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma. <b>2014</b> , 2014, 408459		32
1212	Management algorithms of breast cancer. <b>2014</b> , 120-131		
1211	Neoadjuvant endocrine therapy in breast cancer. <b>2014</b> , 3, 195-203		
1210	Therapeutic targeting of integrin $\alpha 5$ in breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9:7	89
1209	Immunohistochemical study of nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 in invasive breast carcinoma of no special type. <b>2014</b> , 8, 1039-1046		10
1208	Low ER+ breast cancer: Is this a distinct group?. <b>2014</b> , 141, 697-701		33
1207	Metronomic Chemotherapy. <b>2014</b> ,		2
1206	A novel, automated technology for multiplex biomarker imaging and application to breast cancer. <b>2014</b> , 64, 242-55		24
1205	Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women. <b>2014</b> , 135, 2678-86		12
1204	Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study. <b>2014</b> , 135, 669-81		12
1203	Lin28B expression correlates with aggressive clinicopathological characteristics in breast invasive ductal carcinoma. <b>2014</b> , 29, 215-20		20
1202	Potent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion. <b>2014</b> , 110, 2496-505		10
1201	Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. <b>2014</b> , 101, 925-38		30

1200	Pregnancy-associated plasma protein-A expression in human breast cancer. <b>2014</b> , 24, 264-7	26
1199	mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. <b>2014</b> , 10, 443-56	11
1198	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. <b>2014</b> , 16, R65	109
1197	Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression. <b>2014</b> , 290, 1221-9	11
1196	Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy. <b>2014</b> , 14, 826	10
1195	Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. <b>2014</b> , 14, 908	33
1194	Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype. <b>2014</b> , 6, 105	15
1193	Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer. <b>2014</b> , 10, 185	25
1192	The mammary cellular hierarchy and breast cancer. <b>2014</b> , 71, 4301-24	40
1191	Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer. <b>2014</b> , 9, 1339-46	25
1190	Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. <b>2014</b> , 16, R44	36
1189	Breast carcinoma with tubulopapillary features: a variant of papillary carcinoma with a stronger correlation with predictors of adverse prognosis. <b>2014</b> , 22, 47-54	6
1188	Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer. <b>2014</b> , 8, 1707-1712	7
1187	Clinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer. <b>2014</b> , 10, 201-208	4
1186	Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer. <b>2014</b> , 33, 28	17
1185	How to identify patients with increased risk of breast cancer relapse?. <b>2014</b> , 22, 488-97	2
1184	Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. <b>2014</b> , 21, 325-33	11
1183	Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. <b>2014</b> , 21, 52-7	8

1182	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. <b>2014</b> , 23, 234-43	22
1181	Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. <b>2014</b> , 50, 1412-21	19
1180	Outcome of male breast cancer: a matched single-institution series. <b>2014</b> , 14, 371-7	26
1179	Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. <b>2014</b> , 45, 249-58	21
1178	Tissue tablet method: an efficient tissue banking procedure applicable to both molecular analysis and frozen tissue microarray. <b>2014</b> , 45, 143-52	8
1177	Immunohistochemical investigation of the angiogenic proteins VEGF, HIF-1 $\alpha$ and CD34 in invasive ductal carcinoma of the breast. <b>2014</b> , 116, 148-57	13
1176	Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR. <b>2014</b> , 21, 754-60	13
1175	Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. <b>2014</b> , 19, 467-72	14
1174	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. <b>2014</b> , 16, 386-94	14
1173	Clinicopathological features and prognosis of pregnancy associated breast cancer - a matched case control study. <b>2014</b> , 20, 581-90	35
1172	Competing risks analysis in mortality estimation for breast cancer patients from independent risk groups. <b>2014</b> , 17, 259-69	2
1171	Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. <b>2014</b> , 21, 1575-82	10
1170	Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients. <b>2014</b> , 21 Suppl 4, S546-54	46
1169	<sup>18</sup> F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. <b>2014</b> , 24, 610-8	66
1168	Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. <b>2014</b> , 14, 62	76
1167	A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium. <b>2014</b> , 25, 309-19	61
1166	Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using ( <sup>18</sup> F)-FDG PET in luminal HER2-negative breast cancer. <b>2014</b> , 41, 416-27	45
1165	[Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67]. <b>2014</b> , 35, 54-60	3

1164	Low concordance of biomarkers in histopathological and cytological material from breast cancer. <b>2014</b> , 64, 971-80	14
1163	Molecular Testing in Cancer. <b>2014</b> ,	1
1162	Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. <b>2014</b> , 110, 565-72	111
1161	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. <b>2014</b> , 23, 69-75	72
1160	Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. <b>2014</b> , 14, 258-64	31
1159	Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. <b>2014</b> , 27, 554-61	46
1158	Breast cancer classification by proteomic technologies: current state of knowledge. <b>2014</b> , 40, 129-38	98
1157	Time for more optimism in metastatic breast cancer?. <b>2014</b> , 40, 220-8	44
1156	Valeur pronostique des sous-types moléculaires et du Ki67 pour les cancers du sein indemnes d'invasissement ganglionnaire après mastectomie : expérience de l'hôpital René-Huguenin et revue de la littérature. <b>2014</b> , 18, 35-46	
1155	Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. <b>2014</b> , 110, 1139-47	48
1154	Outcomes of patients with breast cancer who present with ipsilateral supraclavicular or internal mammary lymph node metastases. <b>2014</b> , 14, 53-60	21
1153	The potential utility of geminin as a predictive biomarker in breast cancer. <b>2014</b> , 143, 91-8	15
1152	Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. <b>2014</b> , 14, 323-329.e3	26
1151	The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. <b>2014</b> , 67, 222-8	33
1150	Ce que le radiologue doit savoir des nouvelles classifications moléculaires des cancers du sein. <b>2014</b> , 24, 159-164	
1149	Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. <b>2014</b> , 122, 482-9	73
1148	PTEN/PIK3CA genes are frequently mutated in spontaneous and medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumours of tree shrews. <b>2014</b> , 50, 3230-42	19
1147	Inhibitory effects of ginseng saponins on the proliferation of triple negative breast cancer MDA-MB-231 cells. <b>2014</b> , 24, 5409-12	19



1146	Differential immunostaining of various types of breast carcinomas for growth hormone-releasing hormone receptor - Apocrine epithelium and carcinomas emerging as uniformly positive. <b>2014</b> , 122, 824-31	9
1145	Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility. <b>2014</b> , 65, 252-60	12
1144	The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy. <b>2014</b> , 355, 217-23	12
1143	Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?. <b>2014</b> , 92, 235-57	51
1142	Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. <b>2014</b> , 32, 2794-803	197
1141	Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea. <b>2014</b> , 14, 426-34	11
1140	Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. <b>2014</b> , 16, 390-402	58
1139	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. <b>2014</b> , 111, 1532-41	82
1138	Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. <b>2014</b> , 5, 4577	88
1137	Identification of collaborative driver pathways in breast cancer. <b>2014</b> , 15, 605	10
1136	Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <b>2014</b> , 14, 525	17
1135	Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. <b>2014</b> , 14, 550	20
1134	Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. <b>2014</b> , 14, 102	22
1133	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. <b>2014</b> , 14, 28	10
1132	Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. <b>2014</b> , 465, 275-89	30
1131	Association study of susceptibility loci with specific breast cancer subtypes in Chinese women. <b>2014</b> , 146, 503-14	19
1130	Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound. <b>2014</b> , 24, 2227-35	44
1129	Invasive breast carcinomas of no special type with osteoclast-like giant cells frequently have a luminal phenotype. <b>2014</b> , 464, 681-8	15

1128	Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. <b>2014</b> , 145, 101-11	18
1127	Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. <b>2014</b> , 145, 317-30	10
1126	Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women. <b>2014</b> , 25, 881-9	25
1125	A predictive tool to estimate the risk of axillary metastases in breast cancer patients with negative axillary ultrasound. <b>2014</b> , 21, 2229-36	14
1124	Luminal breast cancer classification according to proliferative indices: clinicopathological characteristics and short-term survival analysis. <b>2014</b> , 31, 55	4
1123	Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes. <b>2014</b> , 31, 981	10
1122	Can molecular subtyping replace axillary nodal status as prognostic marker in breast cancer?. <b>2014</b> , 5, 282-9	5
1121	Deregulation of base excision repair gene expression and enhanced proliferation in head and neck squamous cell carcinoma. <b>2014</b> , 35, 5971-83	21
1120	Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer. <b>2014</b> , 35, 8581-9	3
1119	Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. <b>2014</b> , 40, 1089-95	19
1118	Metastatic breast cancer subtypes and central nervous system metastases. <b>2014</b> , 23, 623-8	64
1117	The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer. <b>2014</b> , 70, 1145-51	10
1116	Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. <b>2014</b> , 45, 504-12	24
1115	Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients. <b>2014</b> , 8, 741-52	19
1114	Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?. <b>2014</b> , 155, 927-35	37
1113	Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. <b>2014</b> , 23, 259-63	47
1112	Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. <b>2014</b> , 23, 346-51	18
1111	Personalized medicine: present and future of breast cancer management. <b>2014</b> , 91, 223-33	40

1110	Luminal (Her2 negative) prognostic index and survival of breast cancer patients. <b>2014</b> , 38, 286-90	9
1109	Molecular classification of breast cancer. <b>2014</b> , 465, 1-14	106
1108	Prolactin-induced protein is required for cell cycle progression in breast cancer. <b>2014</b> , 16, 329-42.e1-14	20
1107	Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers. <b>2014</b> , 21, 47-51	6
1106	Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. <b>2014</b> , 16, 432	137
1105	Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients. <b>2014</b> , 45, 2549-59	5
1104	Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer. <b>2014</b> , 114, 153-9	3
1103	Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer. <b>2015</b> , 94, e1720	36
1102	Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer. <b>2015</b> , 10, 2149-2155	22
1101	Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. <b>2015</b> , 17, 80	5
1100	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. <b>2015</b> , 278, 545-70	38
1099	B-crystallin Expression in Breast Cancer is Associated with Brain Metastasis. <b>2015</b> , 1,	22
1098	Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers. <b>2015</b> , 5, 14499	28
1097	Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. <b>2014</b> , 4, 6566	50
1096	Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases. <b>2014</b> , 4, 5122	23
1095	Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study. <b>2015</b> , 10, 1741-1748	14
1094	Identifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decision. <b>2015</b> , 5, 11085	41
1093	TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. <b>2015</b> , 5, 17879	7

1092	Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance. <b>2015</b> , 34, 1146-52	5
1091	Tubal Ligation Induces Quiescence in the Epithelia of the Fallopian Tube Fimbria. <b>2015</b> , 22, 1262-71	3
1090	Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. <b>2015</b> , 15, 822	21
1089	Effect of Ki-67 on Immunohistochemical Classification of Luminal A to Luminal B Subtypes of Breast Carcinoma. <b>2015</b> , 21, 465-72	7
1088	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. <b>2015</b> , 13, 171	11
1087	Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria. <b>2015</b> , 4, 528	7
1086	Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women. <b>2015</b> , 123, 688-96	9
1085	Association of molecular subtypes with breast cancer risk factors: a case-only analysis. <b>2015</b> , 24, 484-90	11
1084	The Impact of Ki-67 on Immunostaining in Classification of Luminal Subtypes of breast Cancer. <b>2015</b> , 21, 463-4	1
1083	Histogram analysis of apparent diffusion coefficient at 3.0t: Correlation with prognostic factors and subtypes of invasive ductal carcinoma. <b>2015</b> , 42, 1666-78	71
1082	Breast Cancer Molecular Subtypes and Oxidative DNA Damage. <b>2015</b> , 23, 696-703	10
1081	Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience. <b>2015</b> , 22, 192-8	9
1080	Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis. <b>2015</b> , 8, 911-9	1
1079	p27(Kip1) and Ser10-phosphorylated p27(Kip1) in breast cancer: clinical significance and expression. <b>2015</b> , 8, 1863-9	1
1078	Apoptotic Molecular Advances in Breast Cancer Management. <b>2015</b> ,	1
1077	Targeted pathways in breast cancer: molecular and protein markers guiding therapeutic decisions. <b>2014</b> , 7, 4-21	21
1076	The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women. <b>2015</b> , 19, 462-6	1
1075	Invasive ductal carcinoma of no special type and its corresponding lymph node metastasis: do they have the same immunophenotypic profile?. <b>2015</b> , 66, 30-7	4

1074	[Predictive value of conventional immuno-histochemical biomarkers in breast cancer]. <b>2015</b> , 143, 724-32	6
1073	Response: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.). <b>2015</b> , 30, 233-4	
1072	Adjuvant chemotherapy may improve survival of patients with luminal A breast cancer and positive lymph nodes. <b>2015</b> , 14, 8563-73	4
1071	Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer. <b>2015</b> , 6, 115	3
1070	High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer. <b>2015</b> , 6, 1130-9	31
1069	Chemopreventive Activity of Ferulago angulate against Breast Tumor in Rats and the Apoptotic Effect of Polycerasoidin in MCF7 Cells: A Bioassay-Guided Approach. <b>2015</b> , 10, e0127434	10
1068	Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells. <b>2015</b> , 10, e0136845	22
1067	Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center. <b>2015</b> , 10, e0131409	40
1066	Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer. <b>2015</b> , 8, 1511-21	11
1065	Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013. <b>2015</b> , 18, 149-59	25
1064	From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?. <b>2015</b> , 153, 45-53	34
1063	Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. <b>2015</b> , 9, 1046-1054	18
1062	Biological Subtypes of Breast Cancer. <b>2015</b> , 1-6	
1061	Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer. <b>2015</b> ,	1
1060	Prediction of Response to Aromatase Inhibitors in Breast Cancer. <b>2015</b> , 191-228	1
1059	Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. <b>2015</b> , 25, 1172-81	25
1058	Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. <b>2015</b> , 152, 57-65	13
1057	Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer. <b>2015</b> , 15, 285	20

1056	Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. <b>2015</b> , 11, 59-66	85
1055	Expression of ribosome-binding protein 1 correlates with shorter survival in Her-2 positive breast cancer. <b>2015</b> , 106, 740-6	22
1054	A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. <b>2015</b> , 21, 5235-44	23
1053	SERS analysis of serum for detection of early and locally advanced breast cancer. <b>2015</b> , 407, 7503-9	52
1052	Is adjuvant chemotherapy omissible in women with T1-2 stage, node-positive, luminal A type breast cancer?. <b>2015</b> , 27, 290-6	5
1051	Correlation Between Clinical-Pathologic Factors and Long-Term Follow-Up in Young Breast Cancer Patients. <b>2015</b> , 8, 265-72	8
1050	Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma. <b>2015</b> , 33, 2924-34	15
1049	Telomere shortening in breast cancer correlates with the pathological features of tumor progression. <b>2015</b> , 34, 627-32	14
1048	Downregulation of Ras GTPase-activating protein 1 is associated with poor survival of breast invasive ductal carcinoma patients. <b>2015</b> , 33, 119-24	13
1047	The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity. <b>2015</b> , 211, 130-7	9
1046	Consenso de seguimiento de pacientes con c�ncer de mama de la Sociedad Espa�ela de Senolog� y Patolog� Mamaria. <b>2015</b> , 28, 24-33	
1045	Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer. <b>2015</b> , 15, 197-203	12
1044	Patient-derived xenograft models of breast cancer and their predictive power. <b>2015</b> , 17, 17	195
1043	Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. <b>2015</b> , 9, 772-82	29
1042	A histomorphologic predictive model for axillary lymph node metastasis in preoperative breast cancer core needle biopsy according to intrinsic subtypes. <b>2015</b> , 46, 246-54	9
1041	Mining cancer gene expression databases for latent information on intronic microRNAs. <b>2015</b> , 9, 473-87	4
1040	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. <b>2015</b> , 26, 81-88	57
1039	Bcl2 and Ki67 refine prognostication in luminal breast cancers. <b>2015</b> , 149, 631-43	13

1038	Luminal-type breast cancer: correlation of apparent diffusion coefficients with the Ki-67 labeling index. <b>2015</b> , 274, 66-73	85
1037	Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls. <b>2015</b> , 21, 315-24	4
1036	p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab. <b>2015</b> , 21, 273-82	8
1035	Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients. <b>2015</b> , 67, 538-47	21
1034	Breast. <b>2015</b> , 183-215	
1033	Molecular phenotypes of DCIS predict overall and invasive recurrence. <b>2015</b> , 26, 1019-1025	74
1032	The origin of breast tumor heterogeneity. <b>2015</b> , 34, 5309-16	90
1031	Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. <b>2015</b> , 150, 209-17	48
1030	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. <b>2015</b> , 20, 713-8	11
1029	DNA repair genes XRCC1 and ERCC1 polymorphisms and the risk of sporadic breast cancer in Han women in the Gansu Province of China. <b>2015</b> , 19, 387-93	8
1028	Gene-Expression-Based Predictors for Breast Cancer. <b>2015</b> , 22, 3418-32	19
1027	miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. <b>2015</b> , 6, e1823	55
1026	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <b>2015</b> , 33, 2772-9	91
1025	[Molecular taxonomy of luminal breast cancer in 2015]. <b>2015</b> , 102, S34-46	5
1024	Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <b>2015</b> , 51, 1481-9	26
1023	Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer. <b>2015</b> , 230, 1708-12	5
1022	Association between <sup>18</sup> F-FDG uptake and molecular subtype of breast cancer. <b>2015</b> , 42, 1371-7	49
1021	High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma. <b>2015</b> , 36, 9919-27	9

1020	Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. <b>2015</b> , 93, 622-30	59
1019	Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients. <b>2015</b> , 68, 825-9	9
1018	Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes. <b>2015</b> , 56, 269-75	38
1017	Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment. <b>2015</b> , 54, 1040-8	21
1016	Can molecular subtyping be used to guide metastatic screening in breast cancer?. <b>2015</b> , 143, 468-70	2
1015	Abnormal expression of the Notch and Wnt/ $\beta$ -catenin signaling pathways in stem-like ALDHCD44 cells correlates highly with Ki-67 expression in breast cancer. <b>2015</b> , 9, 1600-1606	18
1014	High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy. <b>2015</b> , 41, 617-24	17
1013	In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival. <b>2015</b> , 466, 571-80	9
1012	Retrospective analysis of metastatic behaviour of breast cancer subtypes. <b>2015</b> , 150, 547-57	104
1011	Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer. <b>2015</b> , 36, 6833-8	12
1010	High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. <b>2015</b> , 15, 204-11	25
1009	Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. <b>2015</b> , 33, 2035-40	79
1008	An international study to increase concordance in Ki67 scoring. <b>2015</b> , 28, 778-86	168
1007	Osteopontin Regulates VEGFA and ICAM-1 mRNA Expression in Breast Carcinoma. <b>2015</b> , 143, 812-22	11
1006	Resistance to Aromatase Inhibitors in Breast Cancer. <b>2015</b> ,	1
1005	PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. <b>2015</b> , 75, 1289-301	6
1004	The predictive accuracy of PREDICT: a personalized decision-making tool for Southeast Asian women with breast cancer. <b>2015</b> , 94, e593	29
1003	Immunohistochemistry as a surrogate for molecular testing: a review. <b>2015</b> , 23, 81-96	11



1002	Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting. <b>2015</b> , 47, 13-20	13
1001	Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. <b>2015</b> , 112, 1332-9	61
1000	Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer. <b>2015</b> , 36, 28-37	36
999	Ki67--no evidence for its use in node-positive breast cancer. <b>2015</b> , 12, 296-301	47
998	A novel endoscopic-assisted harvesting of pedicled freestyle fasciocutaneous flaps. <b>2015</b> , 94, e592	2
997	New approaches for improving outcomes in breast cancer in Europe. <b>2015</b> , 24, 321-30	37
996	The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. <b>2015</b> , 150, 309-20	25
995	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. <b>2015</b> , 75, 41-50	54
994	Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer. <b>2015</b> , 75, 232-237	13
993	Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. <b>2015</b> , 26, 2442-9	7
992	Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis. <b>2015</b> , 22 Suppl 3, S442-50	46
991	Clinical and molecular complexity of breast cancer metastases. <b>2015</b> , 35, 85-95	86
990	Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. <b>2015</b> , 15, 546	21
989	Biological markers of invasive breast cancer. <b>2016</b> , 46, 99-105	19
988	Precision Molecular Pathology of Breast Cancer. <b>2015</b> ,	3
987	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. <b>2015</b> , 152, 347-56	37
986	Microvascular proliferation in luminal A and basal-like breast cancer subtypes. <b>2015</b> , 68, 891-7	16
985	Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma. <b>2015</b> , 15, 534	14

984	CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping. <b>2015</b> , 21, 1779-81	14
983	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. <b>2015</b> , 8, 54	242
982	Biomarker für Patientinnen mit metastasiertem Mammakarzinom und das PRAEGNANT-Studiennetzwerk. <b>2015</b> , 12, 85-94	
981	Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer. <b>2015</b> , 54, 734-44	7
980	Molecular Classification of Breast Cancer. <b>2015</b> , 137-155	
979	Breast Cancer/Stromal Cells Coculture on Polyelectrolyte Films Emulates Tumor Stages and miRNA Profiles of Clinical Samples. <b>2015</b> , 31, 9991-10001	4
978	Clinical implications of the intrinsic molecular subtypes of breast cancer. <b>2015</b> , 24 Suppl 2, S26-35	450
977	Targeting Mdmx to treat breast cancers with wild-type p53. <b>2015</b> , 6, e1821	28
976	Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. <b>2015</b> , 153, 477-91	141
975	Effects of HER2 genetic polymorphisms on its protein expression in breast cancer. <b>2015</b> , 39, 1123-7	14
974	Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers. <b>2015</b> , 113, 1104-13	15
973	Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. <b>2015</b> , 24 Suppl 2, S136-42	14
972	Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study. <b>2015</b> , 26, 1737-50	14
971	Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. <b>2015</b> , 113, 996-1002	17
970	A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response. <b>2015</b> , 24 Suppl 2, S23-5	2
969	The Breast Tumor Strain Ratio Is a Predictive Parameter for Axillary Lymph Node Metastasis in Patients With Invasive Breast Cancer. <b>2015</b> , 205, W630-8	23
968	The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. <b>2015</b> , 9, 657-74	49
967	Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. <b>2015</b> , 33, 65-73	103

966	Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. <b>2015</b> , 9, 704-14	46
965	Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. <b>2015</b> , 21, 2487-98	102
964	Single-nucleotide polymorphisms in DNA bypass polymerase genes and association with breast cancer and breast cancer subtypes among African Americans and Whites. <b>2015</b> , 149, 181-90	7
963	Fine-needle aspiration cytology samples: a good source of material for evaluating biomarkers in breast cancer. <b>2015</b> , 66, 314-5	6
962	Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. <b>2015</b> , 22, 141-52	31
961	Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells. <b>2015</b> , 22, 129-34	20
960	Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. <b>2015</b> , 22, 71-8	35
959	Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. <b>2015</b> , 22, 520-8	23
958	The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer. <b>2015</b> , 22, 445-51	10
957	Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast. <b>2015</b> , 22, 374-81	38
956	A DNA methylation-based definition of biologically distinct breast cancer subtypes. <b>2015</b> , 9, 555-68	117
955	Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells. <b>2015</b> , 30, 133-41	16
954	Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial. <b>2015</b> , 21, 49-59	39
953	Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy. <b>2015</b> , 21, 147-55	13
952	Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. <b>2015</b> , 22, 399-405	7
951	The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients. <b>2015</b> , 22, 406-12	8
950	Assessment of the Ki67 labeling index: a Japanese validation ring study. <b>2016</b> , 23, 92-100	20
949	Outcome Disparities in African American Compared with European American Women with ER+HER2- Tumors Treated within an Equal-Access Health Care System. <b>2016</b> , 26, 407-16	5

948	Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer. <b>2016</b> , 7, 20496-506	26
947	Analysis of TRRAP as a Potential Molecular Marker and Therapeutic Target for Breast Cancer. <b>2016</b> , 19, 61-7	13
946	Early breast cancer screening using iron/iron oxide-based nanoplatfoms with sub-femtomolar limits of detection. <b>2016</b> , 7, 364-373	13
945	Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. <b>2016</b> , 9, 7-16	18
944	Anatomie pathologique des cancers du sein en phase pr̄coce. <b>2016</b> , 35-48	
943	[Breast cancer in Morocco: phenotypic profile of tumors]. <b>2016</b> , 25, 74	4
942	Ki-67 as a prognostic marker according to breast cancer molecular subtype. <b>2016</b> , 13, 496-504	106
941	Luminal B breast cancer: patterns of recurrence and clinical outcome. <b>2016</b> , 7, 65024-65033	42
940	Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer. <b>2016</b> , 7, 52450-52459	20
939	Expression of PTEN and its correlation with proliferation marker Ki-67 in head and neck cancer. <b>2016</b> , 31, e193-203	10
938	Long non-coding RNAs as prognostic markers in human breast cancer. <b>2016</b> , 7, 20584-96	111
937	Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go. <b>2016</b> , 8,	94
936	Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. <b>2016</b> , 8,	32
935	Correlating Tumor Stiffness with Immunohistochemical Subtypes of Breast Cancers: Prognostic Value of Comb-Push Ultrasound Shear Elastography for Differentiating Luminal Subtypes. <b>2016</b> , 11, e0165003	24
934	A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer. <b>2016</b> , 11, e0150505	45
933	The highly expressed 5'isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. <b>2016</b> , 17, 566	61
932	Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. <b>2016</b> , 7, 1281-94	190
931	Identification of lncRNA as a novel prognostic marker in luminal subtype breast cancer. <b>2016</b> , 9, 7039-7045	32

930	HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo. <b>2016</b> , 7, 45186-45198	37
929	The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value. <b>2016</b> , 24, 159-66	9
928	Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. <b>2016</b> , 68, 422-32	45
927	Meta-analysis of prognostic studies for a biomarker with a study-specific cutoff value. <b>2016</b> , 7, 402-419	6
926	Tumor apparent diffusion coefficient as an imaging biomarker to predict tumor aggressiveness in patients with estrogen-receptor-positive breast cancer. <b>2016</b> , 29, 1070-8	30
925	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <b>2016</b> , 158, 307-21	12
924	Breast Carcinoma-associated Fibroblasts Share Similar Biomarker Profiles in Matched Lymph Node Metastasis. <b>2016</b> , 24, 712-720	8
923	Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. <b>2016</b> , 158, 287-95	10
922	The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression. <b>2016</b> , 28, 1502-19	22
921	CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy. <b>2016</b> , 69, 239-49	5
920	Cytological Criteria for Predicting the Luminal Phenotype of Breast Carcinoma. <b>2016</b> , 60, 406-412	3
919	Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. <b>2016</b> , 14, 244	15
918	How interacting pathways are regulated by miRNAs in breast cancer subtypes. <b>2016</b> , 17, 348	18
917	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <b>2016</b> , 2,	58
916	Novel Immunohistochemical Based Biomarkers in Breast Cancer. <b>2016</b> , 99-119	
915	Oestrogen receptor negativity in breast cancer: a cause or consequence?. <b>2016</b> , 36,	11
914	'Omics Approaches in Breast Cancer Research and Clinical Practice. <b>2016</b> , 23, 356-367	15
913	Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIβ <b>2016</b> , 4, 383-389	6

912	Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology). <b>2016</b> , 11, 248-252	13
911	Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. <b>2016</b> , 16, 398	34
910	Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. <b>2016</b> , 27, 1035-1040	12
909	Sustained Interruption of Anterior Interfaces Between Adipose Tissues and Mammary Glands in Ultrasonography After Complete Pathological Remission After Neoadjuvant Chemotherapy for Primary Breast Cancer. <b>2016</b> , 16, 196-201	1
908	Breast Cancer Subtypes in Patients Aged 70 Years and Older. <b>2016</b> , 34, 197-204	9
907	Intravoxel incoherent motion diffusion-weighted MR imaging of breast cancer: association with histopathological features and subtypes. <b>2016</b> , 89, 20160140	33
906	Personalized Treatment of Breast Cancer. <b>2016</b> ,	2
905	Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. <b>2016</b> , 157, 363-371	102
904	Prognostic factors of early breast cancer. <b>2016</b> , 146, 167-171	1
903	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. <b>2016</b> , 22, 5755-5764	11
902	Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?. <b>2016</b> , 24, 103-7	7
901	[Molecular characterization of breast cancer in clinical practice]. <b>2016</b> , 44, 285-92	1
900	Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer. <b>2016</b> , 35, 50	4
899	Prediction of Indolent Breast Cancer with Favorable Prognostic Factors by Metabolic Profiling Using In Vivo and Ex Vivo MR Metabolomics. <b>2016</b> , 47, 159-174	1
898	Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor. <b>2016</b> , 4, 648-654	20
897	Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. <b>2016</b> , 10, 517-25	13
896	Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs. <b>2016</b> , 100, 460-8	10
895	Emerging Biomarkers of the Future: Changing Clinical Practice for 2020. <b>2016</b> , 8, 60-72	1

894	Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants. <b>2016</b> , 18, 1250-1257	14
893	Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers. <b>2016</b> , 29, 810-23	22
892	Zielgerichtete Therapie des HER2-positiven metastasierten Mammakarzinoms. <b>2016</b> , 13, 26-33	
891	Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences. <b>2016</b> , 25, 1625-1634	22
890	Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer. <b>2016</b> , 12, 2606-2612	28
889	Transcriptomic characterization of differential gene expression in oral squamous cell carcinoma: a meta-analysis of publicly available microarray data sets. <b>2016</b> , 37, 15913	7
888	Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update. <b>2016</b> , 140, 806-14	70
887	Impact of Expression of Vimentin and Axl in Breast Cancer. <b>2016</b> , 16, 520-526.e2	19
886	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <b>2016</b> , 231, 2541-7	10
885	Biomarker assessment and molecular testing for prognostication in breast cancer. <b>2016</b> , 68, 70-85	44
884	Issues Affecting the Loco-regional and Systemic Management of Patients with Invasive Lobular Carcinoma of the Breast. <b>2016</b> , 22, 45-53	13
883	Hypofractionation with no boost after breast conservation in early-stage breast cancer patients. <b>2016</b> , 33, 108	8
882	Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. <b>2016</b> , 46, 1081-1087	10
881	Histogram analysis of apparent diffusion coefficients after neoadjuvant chemotherapy in breast cancer. <b>2016</b> , 34, 657-666	14
880	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <b>2016</b> , 16, 515	10
879	High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. <b>2016</b> , 30, 39-46	64
878	[New prognostic and predictive markers for breast cancer]. <b>2016</b> , 37, 217-222	
877	Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. <b>2016</b> , 16, 734	70

876	H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes. <b>2016</b> , 8, 909-24	23
875	Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. <b>2016</b> , 29, 55-61	3
874	Non-canonical NF- $\kappa$ B pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma. <b>2016</b> , 115, 322-31	16
873	Trends in Breast Cancer Prevention. <b>2016</b> ,	
872	Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer. <b>2016</b> , 69, 86-101	22
871	HER2 expression is a strong independent predictor of nodal metastasis in breast cancer. <b>2016</b> , 28, 219-227	18
870	Klinische Pathologie des Mammakarzinoms. <b>2016</b> , 49, 737-745	
869	Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer. <b>2016</b> , 5, 1873-82	10
868	Molecular imaging using PET and SPECT for identification of breast cancer subtypes. <b>2016</b> , 37, 1116-24	19
867	Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. <b>2016</b> , 95, e3518	17
866	Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. <b>2016</b> , 138, 2346-56	70
865	Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. <b>2016</b> , 118, 544-52	274
864	High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. <b>2016</b> , 37, 669-676	28
863	Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. <b>2016</b> , 158, 179-187	29
862	Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization. <b>2016</b> , 27, 44-51	30
861	The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT. <b>2016</b> , 50, 246-54	5
860	Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs. <b>2016</b> , 28, 587-93	9
859	Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers. <b>2016</b> , 23, 224-30	9



858	[Prognostic factors of early breast cancer]. <b>2016</b> , 146, 167-71	3
857	An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors. <b>2016</b> , 22, 2417-26	7
856	Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?. <b>2016</b> , 42, 333-42	11
855	Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. <b>2016</b> , 468, 493-502	22
854	Ki-67 is a prognostic marker for hormone receptor positive tumors. <b>2016</b> , 18, 996-1002	15
853	Male breast cancer: Looking for better prognostic subgroups. <b>2016</b> , 26, 18-24	30
852	High expression of FOXR2 in breast cancer correlates with poor prognosis. <b>2016</b> , 37, 5991-7	13
851	Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer. <b>2016</b> , 4, 41-8	18
850	Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers. <b>2016</b> , 132, 112-30	25
849	Prediction of low-risk breast cancer using perfusion parameters and apparent diffusion coefficient. <b>2016</b> , 34, 67-74	15
848	Breast Molecular Profiling and Radiotherapy Considerations. <b>2016</b> , 882, 95-124	
847	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. <b>2016</b> , 45, 87-96	150
846	Clinical application of a color map pattern on shear-wave elastography for invasive breast cancer. <b>2016</b> , 25, 44-8	8
845	Association Between Insulin Resistance and Luminal B Subtype Breast Cancer in Postmenopausal Women. <b>2016</b> , 95, e2825	18
844	Role of dietary bioactive natural products in estrogen receptor-positive breast cancer. <b>2016</b> , 40-41, 170-191	35
843	Perfusion Parameters in Dynamic Contrast-enhanced MRI and Apparent Diffusion Coefficient Value in Diffusion-weighted MRI:: Association with Prognostic Factors in Breast Cancer. <b>2016</b> , 23, 446-56	26
842	Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival. <b>2016</b> , 118, 176-82	6
841	Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment. <b>2016</b> , 23, 757-66	14

840	Evaluation of Malignancy Grade of Breast Cancer Using Perflubutane-Enhanced Ultrasonography. <b>2016</b> , 42, 1049-57	10
839	Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review. <b>2016</b> , 43, 36-49	8
838	Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. <b>2016</b> , 21, 28-32	63
837	Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer. <b>2016</b> , 468, 409-16	5
836	Loss of antigenicity with tissue age in breast cancer. <b>2016</b> , 96, 264-9	23
835	The impact of preoperative axillary ultrasonography in T1 breast tumours. <b>2016</b> , 26, 1073-81	12
834	Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer. <b>2016</b> , 142, 263-72	9
833	Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer. <b>2016</b> , 23, 745-51	20
832	The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index. <b>2016</b> , 69, 255-9	20
831	Bioengineered silk scaffolds in 3D tissue modeling with focus on mammary tissues. <b>2016</b> , 59, 1168-1180	28
830	High Ki67 expression is an independent good prognostic marker in colorectal cancer. <b>2016</b> , 69, 209-14	71
829	Ki-67 as a Prognostic Factor in Feline Mammary Carcinoma: What Is the Optimal Cutoff Value?. <b>2016</b> , 53, 37-43	20
828	Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status. <b>2017</b> , 45, 94-102	38
827	The Performance of Ki-67 Labeling Index in Different Specimen Categories of Invasive Ductal Carcinoma of the Breast Using 2 Scoring Methods. <b>2017</b> , 25, 86-90	4
826	Oncoplastic surgery for inner quadrant breast cancer: fish-hook incision rotation flap. <b>2017</b> , 87, E129-E133	7
825	Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. <b>2017</b> , 32, 79-86	10
824	Molecular characterization of CD44/CD24/Ck/CD45 cells in benign and malignant breast lesions. <b>2017</b> , 470, 311-322	12
823	Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. <b>2017</b> , 162, 1-10	27

822	A novel non-parametric method for uncertainty evaluation of correlation-based molecular signatures: its application on PAM50 algorithm. <b>2017</b> , 33, 693-700	10
821	MR Imaging Findings in Molecular Subtypes of Breast Cancer According to BIRADS System. <b>2017</b> , 23, 421-428	15
820	Preoperative MRI Evaluation of Axillary Lymph Nodes in Invasive Ductal Carcinoma: Comparison of Luminal A Versus Luminal B Subtypes in a Paradigm Using Ki-67 and Receptor Status. <b>2017</b> , 208, 910-915	5
819	The role of IL17B-IL17RB signaling pathway in breast cancer. <b>2017</b> , 88, 795-803	43
818	First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. <b>2017</b> , 17, 3	20
817	MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. <b>2017</b> , 30, 682-697	38
816	P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice. <b>2017</b> , 30, 698-709	10
815	FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis. <b>2017</b> , 162, 243-253	12
814	Prognostic significance of Ki67 in Chinese women diagnosed with ER/HER2 breast cancers by the 2015 St. Gallen consensus classification. <b>2017</b> , 17, 28	5
813	Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. <b>2017</b> , 17, 124	42
812	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. <b>2017</b> , 15, 30	12
811	The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer. <b>2017</b> , 118, 2559-2570	63
810	Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer. <b>2017</b> , 63, 40-45	21
809	Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer. <b>2017</b> , 456, 76-86	27
808	Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. <b>2017</b> , 70, 622-631	18
807	Axillary Skip Metastases and the False-Negative Rate of Sentinel Lymph Node Biopsy in Patients With Breast Cancer Are Related to Negative ALDH-1 Expression and Ki-67 Expression. <b>2017</b> , 25, 397-405	3
806	Computer-aided Diagnosis-generated Kinetic Features of Breast Cancer at Preoperative MR Imaging: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer. <b>2017</b> , 284, 45-54	25
805	Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab. <b>2017</b> , 164, 221-229	8

804	Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. <b>2017</b> , 71, 446-452	15
803	Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer. <b>2017</b> , 24, 748-755	6
802	Vascular Smooth Muscle Cell Maturation Stage and Ki-67 Index are Diagnostic Biomarkers for Pathologic Grade of Ovarian Teratoma. <b>2017</b> , 36, 582-592	6
801	Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival. <b>2017</b> , 19, 1232-1240	17
800	Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature. <b>2017</b> , 113, 283-291	26
799	Effect of Ki-67 assessment in the distribution of breast cancer subtypes: Evaluation in a cohort of Latin American patients. <b>2017</b> , 6, 503-509	9
798	Quality assurance trials for Ki67 assessment in pathology. <b>2017</b> , 471, 501-508	18
797	Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. <b>2017</b> , 164, 341-348	33
796	Colorectal cancer subtypes: Translation to routine clinical pathology. <b>2017</b> , 57, 1-7	24
795	Expression Pattern of Smad4/GATA3 as a Predictor of Survival in Invasive Ductal Carcinoma of the Breast. <b>2017</b> , 84, 130-138	5
794	Validity and reliability of Ki-67 assessment in oestrogen receptor positive breast cancer. <b>2017</b> , 49, 371-378	3
793	An Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer. <b>2017</b> , 16, 1967-1978	16
792	Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers. <b>2017</b> , 13, 4708-4712	23
791	Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <b>2017</b> , 35, 21-26	12
790	Fibrotic focus: An important parameter for accurate prediction of a high level of tumor-associated macrophage infiltration in invasive ductal carcinoma of the breast. <b>2017</b> , 67, 331-341	4
789	Clinical utility of gene-expression signatures in early stage breast cancer. <b>2017</b> , 14, 595-610	127
788	Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. <b>2017</b> , 165, 355-364	18
787	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <b>2017</b> , 163, 535-544	14

- 786 New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. **2017**, 141, 490-498 37
- 785 Expression of oxysterol pathway genes in oestrogen-positive breast carcinomas. **2017**, 86, 852-861 2
- 784 Molecular Classification and Testing of Breast Carcinoma. **2017**, 215-231
- 783 A Practical Approach to the Use of Immunohistochemistry in the Diagnosis and Management of Breast Disease. **2017**, 189-214
- 782 Molecular subtypes of breast cancer, do they differ in different age groups among Egyptian female individuals? (retrospective study). **2017**, 37, 160-164
- 781 Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes. **2017**, 10, 904-910 17
- 780 Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. **2017**, 23, 7288-7300 20
- 779 Bim may be a poor prognostic biomarker in breast cancer patients especially in those with luminal A tumors. **2017**, 19, 411-418 5
- 778 LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. **2017**, 28, 2977-2984 93
- 777 Biologic Profiles of Invasive Breast Cancers Detected Only With Digital Breast Tomosynthesis. **2017**, 209, 1411-1418 22
- 776 Interlaboratory variability of Ki67 staining in breast cancer. **2017**, 84, 219-227 45
- 775 Breast cancer in young women and prognosis: How important are proliferation markers?. **2017**, 84, 278-289 15
- 774 Splice variants of cytosolic polyadenylation element-binding protein 2 (CPEB2) differentially regulate pathways linked to cancer metastasis. **2017**, 292, 17909-17918 9
- 773 The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer. **2017**, 7, 11625 32
- 772 Visualizing Breast Cancer Cell Proliferation and Invasion for Assessing Drug Efficacy with a Fluorescent Nanoprobe. **2017**, 89, 10601-10607 21
- 771 Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ. **2017**, 25, 543-547 4
- 770 Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival. **2017**, 32, 13
- 769 Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods. **2017**, 148, 108-118 9

768	F-Fluoromisonidazole positron emission tomography (FMISO-PET) may reflect hypoxia and cell proliferation activity in oral squamous cell carcinoma. <b>2017</b> , 124, 261-270	8
767	[F]FDG PET/CT features for the molecular characterization of primary breast tumors. <b>2017</b> , 44, 1945-1954	40
766	Integrated diagnostic network construction reveals a 4-gene panel and 5 cancer hallmarks driving breast cancer heterogeneity. <b>2017</b> , 7, 6827	17
765	Percentage change of primary tumor on 18F-FDG PET/CT as a prognostic factor for invasive ductal breast cancer with axillary lymph node metastasis: Comparison with MRI. <b>2017</b> , 96, e7657	4
764	Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. <b>2017</b> , 51, 781-790	27
763	Correlation of 18F-FDG PET/CT with pathological features and survival in primary breast cancer. <b>2017</b> , 38, 694-700	8
762	Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study. <b>2017</b> , 166, 613-622	20
761	Differentiation Between Luminal-A and Luminal-B Breast Cancer Using Intravoxel Incoherent Motion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging. <b>2017</b> , 24, 1575-1581	19
760	The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer. <b>2017</b> , 7, 6597	15
759	Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. <b>2018</b> , 25, 828-840	53
758	Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate-hydroxylase expression. <b>2017</b> , 108, 2454-2461	10
757	The Pathology Report. <b>2017</b> , 157-168	1
756	Adjuvant Systemic Therapies by Subtypes: Guidelines. <b>2017</b> , 535-539	
755	De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. <b>2017</b> , 34 Suppl 1, S13-S18	6
754	Managing BRCA Mutation Carriers. <b>2017</b> ,	
753	Treatment for the endocrine resistant breast cancer: Current options and future perspectives. <b>2017</b> , 172, 166-175	26
752	Survivin expression pattern in the intestine of normoxic and ischemic rats. <b>2017</b> , 17, 76	8
751	hypermethylation is an independent prognostic biomarker in breast cancer. <b>2017</b> , 9, 7	10

750	Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. <b>2017</b> , 165, 573-583	100
749	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <b>2017</b> , 10, 589-598	13
748	Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts. <b>2017</b> , 8, 4-15	15
747	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <b>2017</b> , 31, 114-120	42
746	Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients. <b>2017</b> , 56, 59-67	14
745	How may targeted proteomics complement genomic data in breast cancer?. <b>2017</b> , 14, 43-54	11
744	Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. <b>2017</b> , 17, 41-47	17
743	The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy. <b>2017</b> , 24, 384-392	0
742	Expression of cell polarity protein scribble differently affects prognosis in primary tumor and lymph node metastasis of breast cancer patients. <b>2017</b> , 24, 393-399	5
741	Diagnostic performance of diffusion tensor imaging parameters in breast cancer and correlation with the prognostic factors. <b>2017</b> , 45, 660-672	22
740	Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer. <b>2017</b> , 241, 350-361	49
739	CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma. <b>2017</b> , 470, 81-90	4
738	Over-using chemotherapy in the adjuvant setting. <b>2017</b> , 31, 303-308	8
737	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. <b>2017</b> , 23, 2991-3002	33
736	Breast Pathology. <b>2017</b> ,	1
735	The Reliability of Core-Needle Biopsy in Assessment of Hormone Receptor, HER2, and Ki-67 in Breast Carcinoma. <b>2017</b> , 102, 522-529	
734	Novel gene selection method for breast cancer intrinsic subtypes from two large cohort study. <b>2017</b> ,	1
733	Entropy is a Simple Measure of the Antibody Profile and is an Indicator of Health Status: A Proof of Concept. <b>2017</b> , 7, 18060	5

732	Targeting breast cancer cells with a CuInS/ZnS quantum dot-labeled Ki-67 bioprobe. <b>2018</b> , 15, 2471-2476	9
731	MicroRNA-10b expression in node-negative breast cancer-correlation with metastasis and angiogenesis. <b>2017</b> , 14, 5845-5852	11
730	Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway. <b>2017</b> , 23, 4182-4191	14
729	BI-RADS 3-5 microcalcifications can preoperatively predict breast cancer HER2 and Luminal a molecular subtype. <b>2017</b> , 8, 13855-13862	19
728	Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer.. <b>2017</b> , 1, 1-19	6
727	Breast Cancer: From Transcriptional Control to Clinical Outcome. <b>2017</b> ,	1
726	ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. <b>2017</b> , 10, 4859-4867	8
725	Clinicopathological and Imaging Features of Breast Cancer in Korean Women under 40 Years of Age. <b>2017</b> , 76, 375	4
724	Prognostic immune-related gene models for breast cancer: a pooled analysis. <b>2017</b> , 10, 4423-4433	7
723	Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. <b>2017</b> , 5,	36
722	Ductal Carcinoma Biology, Biomarkers, and Diagnosis. <b>2017</b> , 7, 248	61
721	Concordance of immunohistochemistry between core needle biopsy and surgical resection of breast cancer. <b>2017</b> , 47, 1791-1796	3
720	spp.: A Promising Adjuvant Treatment for Breast Cancer. <b>2017</b> , 4,	14
719	Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases. <b>2017</b> , 8, 3828-3837	17
718	Estimation of T2* Relaxation Time of Breast Cancer: Correlation with Clinical, Imaging and Pathological Features. <b>2017</b> , 18, 238-248	17
717	A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method. <b>2017</b> , 12, e0172031	25
716	Ancestry as a potential modifier of gene expression in breast tumors from Colombian women. <b>2017</b> , 12, e0183179	14
715	Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer. <b>2017</b> , 12, e0171683	80



714	MRI texture analysis in differentiating luminal A and luminal B breast cancer molecular subtypes - a feasibility study. <b>2017</b> , 17, 69	58
713	Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers. <b>2017</b> , 17, 662	2
712	Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin. <b>2017</b> , 19, 86	34
711	Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya. <b>2017</b> , 45, 19	6
710	Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients. <b>2018</b> , 8, 250-256	3
709	Pathway-based classification of breast cancer subtypes. <b>2017</b> , 22, 1697-1712	11
708	Application of artificial neural networks for predicting presence of non-sentinel lymph node metastases in breast cancer patients with positive sentinel lymph node biopsies. <b>2017</b> , 13, 1399-1407	12
707	Prevalence of biological types of breast cancer and their influence on disease staging and therapeutic management - a single-center study. <b>2017</b> , 68, 16-25	3
706	Prediction of low-risk breast cancer using quantitative DCE-MRI and its pathological basis. <b>2017</b> , 8, 114360-114370	370
705	Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. <b>2017</b> , 8, 18680-18698	15
704	Put Some PEPI in Your Step: Ki67's Long Road to Respectability. <b>2017</b> , 35, 1031-1032	6
703	The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67. <b>2017</b> , 8, 65064-65076	41
702	Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer. <b>2018</b> , 45, 692-705	24
701	Association between enhancement patterns and parameters of contrast-enhanced ultrasound and microvessel distribution in breast cancer. <b>2018</b> , 15, 5643-5649	17
700	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. <b>2018</b> , 24, 2328-2341	32
699	The extracellular domain of Her2 in serum as a biomarker of breast cancer. <b>2018</b> , 98, 696-707	35
698	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. <b>2018</b> , 143, 746-757	9
697	Loss of p27 expression is associated with poor prognosis in patients with taxane-treated breast cancer. <b>2018</b> , 214, 565-571	4

696	Patterns of breast cancer relapse in accordance to biological subtype. <b>2018</b> , 144, 1347-1355	30
695	Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. <b>2018</b> , 16, 86	25
694	microRNA-10b expression and its correlation with molecular subtypes of early invasive ductal carcinoma. <b>2018</b> , 15, 2851-2859	3
693	Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. <b>2018</b> , 73, 545-558	12
692	Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer. <b>2018</b> , 71, 787-794	17
691	ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1. <b>2018</b> , 12, 896-912	29
690	Morphological MR features and quantitative ADC evaluation in invasive breast cancer: Correlation with prognostic factors. <b>2018</b> , 50, 141-146	2
689	Her2Net: A Deep Framework for Semantic Segmentation and Classification of Cell Membranes and Nuclei in Breast Cancer Evaluation. <b>2018</b> , 27, 2189-2200	69
688	Ancillary Prognostic and Predictive Testing in Breast Cancer: Focus on Discordant, Unusual, and Borderline Results. <b>2018</b> , 11, 147-176	4
687	Correlation of FANCM expression with clinical factors in luminal B breast cancer. <b>2018</b> , 25, 431-437	1
686	Carbon nanospheres mediated nuclear delivery of SMAR1 protein (DNA binding domain) controls breast tumor in mice model. <b>2018</b> , 13, 353-372	3
685	Adjuvant and Neoadjuvant Systemic Therapies for Early-Stage Breast Cancer. <b>2018</b> , 752-762.e4	
684	Endocrine Therapy for Breast Cancer. <b>2018</b> , 907-923.e6	2
683	Adjuvant Chemotherapy. <b>2018</b> , 439-445	
682	An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG). <b>2018</b> , 57, 83-89	21
681	Invasive Breast Cancer: Prognostic Value of Peritumoral Edema Identified at Preoperative MR Imaging. <b>2018</b> , 287, 68-75	39
680	Diagnostic and prognostic values of contrast-enhanced ultrasound combined with diffusion-weighted magnetic resonance imaging in different subtypes of breast cancer. <b>2018</b> , 42, 105-114	3
679	Frequency of breast cancer subtypes among African American women in the AMBER consortium. <b>2018</b> , 20, 12	21

678	Molecular Classification of Breast Cancer. <b>2018</b> , 13, 325-338	48
677	Evaluation of association between degree of background parenchymal enhancement on MRI and breast cancer subtype. <b>2018</b> , 51, 307-310	9
676	Diffusion tensor magnetic resonance imaging of breast cancer: associations between diffusion metrics and histological prognostic factors. <b>2018</b> , 28, 3185-3193	12
675	A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. <b>2018</b> , 2, 7	51
674	Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. <b>2018</b> , 14, 849-859	13
673	Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature. <b>2018</b> , 215, 171-178	11
672	Steroid metabolism in breast cancer: Where are we and what are we missing?. <b>2018</b> , 466, 86-97	23
671	Performance of 4 Immunohistochemical Phosphohistone H3 Antibodies for Marking Mitotic Figures in Breast Cancer. <b>2018</b> , 26, 20-26	7
670	Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution. <b>2018</b> , 27, 3-10	18
669	Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. <b>2018</b> , 167, 459-468	38
668	Clinicopathological study of a dimorphic variant of breast carcinoma. <b>2018</b> , 25, 151-158	1
667	Divergent Activity of the Pseudogene in ER-Positive and Negative Breast Cancer. <b>2018</b> , 16, 78-89	14
666	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. <b>2018</b> , 31, 299-306	9
665	Cell Cycle-Dependent Tumor Engraftment and Migration Are Enabled by Aurora-A. <b>2018</b> , 16, 16-31	18
664	Immunohistochemical versus molecular (Blueprint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. <b>2018</b> , 167, 123-131	39
663	Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. <b>2018</b> , 167, 31-37	14
662	Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis. <b>2018</b> , 472, 195-203	9
661	Texture analysis of high-resolution dedicated breast F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer. <b>2018</b> , 45, 196-206	32

660	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. <b>2018</b> , 24, 701-716	13
659	Molecular subtyping of breast cancer improves identification of both high and low risk patients. <b>2018</b> , 57, 58-66	8
658	Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers. <b>2018</b> , 48, 226-236	26
657	Selective isolation and noninvasive analysis of circulating cancer stem cells through Raman imaging. <b>2018</b> , 102, 372-382	42
656	Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer. <b>2018</b> , 18, e643-e650	5
655	Diffusion-weighted imaging features of breast tumours and the surrounding stroma reflect intrinsic heterogeneous characteristics of molecular subtypes in breast cancer. <b>2018</b> , 31, e3869	18
654	Digital image analysis in breast pathology-from image processing techniques to artificial intelligence. <b>2018</b> , 194, 19-35	128
653	Response letter to: Questions about Ki67 staining in luminal breast cancer. <b>2018</b> , 167, 601	
652	Neoadjuvant Endocrine Therapy: Who Benefits Most?. <b>2018</b> , 27, 121-140	2
651	Molecular Subtypes and Local-Regional Control of Breast Cancer. <b>2018</b> , 27, 95-120	180
650	Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals. <b>2018</b> , 2, 97-107	2
649	Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion. <b>2018</b> , 97, e13055	12
648	Evaluating the current evidence to support therapeutic mastoplasty or breast-conserving surgery as an alternative to mastectomy in the treatment of multifocal and multicentric breast cancers. <b>2018</b> , 7, 525-535	7
647	BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score. <b>2018</b> , 18, 14	3
646	PI3K/Akt/mTOR signalling pathway activation in patients with ER-positive, metachronous, contralateral breast cancer treated with hormone therapy. <b>2019</b> , 17, 1962-1968	12
645	Distinct expression profiles and functions of Kindlins in breast cancer. <b>2018</b> , 37, 281	10
644	Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. <b>2018</b> , 8, 609	11
643	OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor-positive breast carcinoma. <b>2018</b> , 109, 3350-3359	25

642	Detection of noncalcified breast cancer in patients with extremely dense breasts using digital breast tomosynthesis compared with full-field digital mammography. <b>2019</b> , 92, 20180101	6
641	VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX. <b>2018</b> , 16, 109	14
640	Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray. <b>2018</b> , 9, 377-388	5
639	Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma. <b>2018</b> , 62,	23
638	Scinderin-knockdown inhibits proliferation and promotes apoptosis in human breast carcinoma cells. <b>2018</b> , 16, 3207-3214	3
637	Does loss of hormonal receptors influence the pathophysiological characteristics of the HER-2 breast cancer phenotype?. <b>2018</b> , 25, 439-444	1
636	Breast Cancer Tissue Markers, Genomic Profiling, and Other Prognostic Factors: A Primer for Radiologists. <b>2018</b> , 38, 1902-1920	19
635	Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center. <b>2018</b> , 2018, 2047089	1
634	[Ki67: biological intertumor variance versus variance of assay]. <b>2018</b> , 39, 272-277	7
633	TIM-3 expression in breast cancer. <b>2018</b> , 7, e1502128	34
632	microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy. <b>2018</b> , 20, 17	30
631	Could local surgery improve survival in de novo stage IV breast cancer?. <b>2018</b> , 18, 885	14
630	Intravoxel incoherent motion magnetic resonance imaging for breast cancer: A comparison with benign lesions and evaluation of heterogeneity in different tumor regions with prognostic factors and molecular classification. <b>2018</b> , 16, 5100-5112	12
629	Breast MRI for prediction of lymphovascular invasion in breast cancer patients with clinically negative axillary lymph nodes. <b>2018</b> , 107, 111-118	12
628	The prognostic effects of somatic mutations in ER-positive breast cancer. <b>2018</b> , 9, 3476	51
627	Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment. <b>2018</b> , 13, 63	3
626	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. <b>2018</b> , 24, 4887-4899	35
625	Patterns of malignant non-mass enhancement on 3-T breast MRI help predict invasiveness: using the BI-RADS lexicon fifth edition. <b>2018</b> , 59, 1292-1299	3

624	Breast Carcinoma: Updates in Molecular Profiling 2018. <b>2018</b> , 38, 401-420	17
623	Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer. <b>2018</b> , 144, 1547-1559	2
622	Updates in the Evaluation and Management of Breast Cancer. <b>2018</b> , 93, 794-807	28
621	Stem cells purified from human induced pluripotent stem cell-derived neural crest-like cells promote peripheral nerve regeneration. <b>2018</b> , 8, 10071	28
620	DCE-MRI Pharmacokinetic-Based Phenotyping of Invasive Ductal Carcinoma: A Radiomic Study for Prediction of Histological Outcomes. <b>2018</b> , 2018, 5076269	25
619	Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists. <b>2018</b> , 25, 768-777	2
618	Intracellular hypoxia measured by F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer. <b>2018</b> , 20, 78	13
617	Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases. <b>2018</b> , 66, 787-799	8
616	Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. <b>2018</b> , 473, 275-283	5
615	In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab-paclitaxel on triple-negative and luminal A breast cancer cells. <b>2018</b> , 40, 527-535	2
614	Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. <b>2018</b> , 9,	3
613	Impact of Genomics on Personalization of Breast Cancer Care. <b>2018</b> , 331-372	1
612	A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response. <b>2018</b> , 19,	19
611	Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma. <b>2018</b> , 95, 229-238	9
610	Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. <b>2018</b> , 2, 162-174	15
609	A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. <b>2018</b> , 119, 508-516	43
608	Association of APEX1 and OGG1 gene polymorphisms with breast cancer risk among Han women in the Gansu Province of China. <b>2018</b> , 19, 67	7
607	microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. <b>2018</b> , 17, 9	63

606	Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. <b>2018</b> , 16, 1	50
605	Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model. <b>2018</b> , 16, 1	31
604	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. <b>2018</b> , 67, 63-70	45
603	Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer. <b>2018</b> , 39, 680-690	17
602	Exercise Training-induced Modulation in Microenvironment of Rat Mammary Neoplasms. <b>2018</b> , 39, 885-892	4
601	Role of activating transcription factor 3 and its interacting proteins under physiological and pathological conditions. <b>2018</b> , 120, 310-317	36
600	The prognostic value of androgen receptors in breast cancer subtypes. <b>2018</b> , 172, 283-296	17
599	Design of functionalized cyclic peptides through orthogonal click reactions for cell culture and targeting applications. <b>2018</b> , 54, 6923-6926	8
598	Cold atmospheric plasma conveys selectivity on triple negative breast cancer cells both in vitro and in vivo. <b>2018</b> , 124, 205-213	54
597	Are preoperative serum CA15-3 levels different in breast cancer subgroups?. <b>2019</b> , 43, 115-122	4
596	Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. <b>2019</b> , 143, 206-211	13
595	Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. <b>2019</b> , 178, 451-458	14
594	The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. <b>2019</b> , 475, 709-725	7
593	Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention. <b>2019</b> , 38, e100852	32
592	Practical Breast Pathology. <b>2019</b> ,	
591	Immunohistochemistry in Breast Cancer. <b>2019</b> , 173-192	1
590	Exploring the Molecular Mechanism of the Drug-Treated Breast Cancer Based on Gene Expression Microarray. <b>2019</b> , 9,	6
589	Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy. <b>2019</b> , 11, 5677-5690	1

588	Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. <b>2019</b> , 5, 20	14
587	Molecular Classification and Prognostic Signatures of Breast Tumors. <b>2019</b> , 129-138	
586	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. <b>2019</b> , 117, 132-139	6
585	Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis. <b>2019</b> , 8,	22
584	Clinical and epidemiologic factors associated with breast cancer and its subtypes among Northeast Chinese women. <b>2019</b> , 8, 7431-7445	7
583	Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1. <b>2019</b> , 11, 217-227	3
582	Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer. <b>2019</b> , 33, 2133-2139	1
581	Molecular subtyping of mammary Paget's disease using immunohistochemistry. <b>2019</b> , 40, 440-446	4
580	External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China. <b>2019</b> , 19, 978	4
579	Diagnostic value of diffusion-weighted imaging-derived apparent diffusion coefficient and its association with histological prognostic factors in breast cancer. <b>2019</b> , 18, 3295-3303	5
578	MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. <b>2019</b> , 21, 1015-1035	38
577	Dysregulated expression of repetitive DNA in ER+/HER2- breast cancer. <b>2019</b> , 239, 36-45	9
576	Clinical outcomes of an intraoperative surgical margin assessment using the fresh frozen section method in patients with invasive breast cancer undergoing breast-conserving surgery - a single center analysis. <b>2019</b> , 9, 13441	14
575	Atypical ubiquitin-binding protein SHARPIN promotes breast cancer progression. <b>2019</b> , 119, 109414	10
574	Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma. <b>2019</b> , 98, e13554	9
573	Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America. <b>2019</b> , 13, 896	5
572	[Selection of Radiomic Features for the Classification of Triple-negative Breast Cancer Based on Radiogenomics]. <b>2019</b> , 75, 24-31	1
571	Breast Cancer Pathology. <b>2019</b> , 87-127	1



570	Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response. <b>2019</b> , 19, 601	9
569	Should a Multigene Signature be Used in all Luminal Early Breast Cancers. <b>2019</b> , 9, 454	2
568	Patient-Derived Xenograft Models of Breast Cancer and Their Application. <b>2019</b> , 8,	53
567	Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. <b>2019</b> , 19, 549	5
566	Biomarkers in Cancer Therapy. <b>2019</b> ,	1
565	Optoacoustic imaging of the breast: correlation with histopathology and histopathologic biomarkers. <b>2019</b> , 29, 6728-6740	9
564	PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. <b>2019</b> , 9, 7956	21
563	Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer. <b>2019</b> , 19, 521	6
562	FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors - implications for therapy of luminal breast cancer. <b>2019</b> , 38, 230	20
561	Association of TNFAIP8 gene polymorphisms with endometrial cancer in northern Chinese women. <b>2019</b> , 19, 105	5
560	Biomarkers for Breast Cancer Treatment. <b>2019</b> , 115-124	
559	Comprehensive analysis of the aberrantly expressed lncRNA-associated ceRNA network in breast cancer. <b>2019</b> , 19, 4697-4710	12
558	Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells. <b>2019</b> , 8,	23
557	Immunotherapy in breast cancer: Current status and future directions. <b>2019</b> , 143, 295-349	24
556	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. <b>2019</b> , 120, 913-921	7
555	Survival outcome of adjuvant endocrine therapy alone for patients with lymph node-positive, hormone-responsive, HER2-negative breast cancer. <b>2019</b> , 42, 914-921	1
554	Differences in intra-tumoral macrophage infiltration and radiotherapy response among intrinsic subtypes in pT1-T2 breast cancers treated with breast-conserving surgery. <b>2019</b> , 475, 151-162	10
553	Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer. <b>2019</b> , 10, 1110-1116	6

552	Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment. <b>2019</b> , 14, e0212309	15
551	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <b>2019</b> , 175, 617-625	20
550	Differences in clinicopathologic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes. <b>2019</b> , 30, 417-424	2
549	Upregulated expression of AT-rich interactive domain-containing protein 1B predicts poor prognosis in patients with triple-negative breast cancer. <b>2019</b> , 17, 3289-3295	4
548	Massive integrative gene set analysis enables functional characterization of breast cancer subtypes. <b>2019</b> , 93, 103157	4
547	Microcalcification and BMP-2 in breast cancer: correlation with clinicopathological features and outcomes. <b>2019</b> , 12, 2023-2033	7
546	Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge. <b>2019</b> , 54, 111-121	109
545	Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type. <b>2019</b> , 113, 148-152	22
544	Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer. <b>2019</b> , 299, 1405-1413	9
543	Genome-wide methylotyping resolves breast cancer epigenetic heterogeneity and suggests novel therapeutic perspectives. <b>2019</b> , 11, 605-617	14
542	Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer. <b>2020</b> , 107, 33-43	15
541	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. <b>2019</b> , 21, 153	7
540	Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer. <b>2019</b> , 9,	99
539	Dual time point F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (F-FDG PET/CT) in primary breast cancer. <b>2019</b> , 19, 1146	4
538	The Exosome And Breast Cancer Cell Plasticity. <b>2019</b> , 12, 9817-9825	7
537	Application of Single-Cell Omics in Breast Cancer. <b>2019</b> , 69-103	4
536	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. <b>2019</b> , 8,	7
535	Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder. <b>2019</b> , 50, 848-854	4

534	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <b>2019</b> , 24, 165-171	13
533	KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer. <b>2019</b> , 32, 172-184	2
532	PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts. <b>2019</b> , 28, 798-806	8
531	Antitumor Action of Amygdalin on Human Breast Cancer Cells by Selective Sensitization to Oxidative Stress. <b>2019</b> , 71, 483-490	17
530	Adjuvant Chemotherapy for HER2-Negative Early-Stage Breast Cancer. <b>2019</b> , 357-381	
529	Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. <b>2019</b> , 85, 299-308	13
528	Association Between Postpartum Breast Cancer Diagnosis and Metastasis and the Clinical Features Underlying Risk. <b>2019</b> , 2, e186997	46
527	p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value. <b>2019</b> , 26, 624-638.e8	29
526	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <b>2019</b> , 174, 453-461	7
525	Single Cell Omics of Breast Cancer: An Update on Characterization and Diagnosis. <b>2019</b> , 34, 3-18	10
524	Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery. <b>2019</b> , 236, 288-299	5
523	Microvessel density in breast cancer: the impact of field area on prognostic informativeness. <b>2019</b> , 72, 304-310	4
522	PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer. <b>2019</b> , 173, 533-543	19
521	Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients. <b>2019</b> , 45, 68-77	12
520	Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity. <b>2019</b> , 32, 354-366	10
519	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. <b>2019</b> , 173, 255-266	48
518	Subtypes in BRCA-mutated breast cancer. <b>2019</b> , 84, 192-201	13
517	Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44 years. <b>2019</b> , 26, 386-396	6

516	ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. <b>2019</b> , 58, 175-185	17
515	Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery. <b>2019</b> , 134, 10-21	9
514	Single-cell mobility shift electrophoresis reports protein localization to the cell membrane. <b>2019</b> , 144, 972-979	6
513	Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. <b>2019</b> , 173, 111-122	6
512	Association Between Shear Wave Elastography of Virtual Touch Tissue Imaging Quantification Parameters and the Ki-67 Proliferation Status in Luminal-Type Breast Cancer. <b>2019</b> , 38, 73-80	4
511	Decision Making Criteria in Oncology. <b>2020</b> , 98, 370-378	41
510	Response to immunohistochemical markers' conversion after neoadjuvant chemotherapy in breast cancer patients: association between imaging and histopathologic analysis. <b>2020</b> , 22, 91-102	1
509	Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. <b>2020</b> , 179, 3-10	21
508	Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 540-544	9-7 49
507	The Relationship Between MRI Findings and Molecular Subtypes in Women With Breast Cancer. <b>2020</b> , 49, 417-421	6
506	Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer. <b>2020</b> , 26, 1499-1510	4
505	Dermoglandular rotation flap with subaxillary advancement flap as an oncoplastic technique for breast cancer. <b>2020</b> , 26, 420-426	1
504	Invasive ductal breast cancer: preoperative predict Ki-67 index based on radiomics of ADC maps. <b>2020</b> , 125, 109-116	29
503	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. <b>2020</b> , 26, 110-121	57
502	Role of androgen and microRNA in triple-negative breast cancer. <b>2020</b> , 39, 15-27	4
501	Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment. <b>2020</b> , 76, 650-660	3
500	Role of CD44 in breast cancer. <b>2020</b> , 39, 1-13	28
499	Expression of UTX Indicates Poor Prognosis in Patients With Luminal Breast Cancer and is Associated With MMP-11 Expression. <b>2020</b> , 28, 544-550	1

498	Stromal Collagen Content in Breast Tumors Correlates With In Vivo Diffusion-Weighted Imaging: A Comparison of Multi b-Value DWI With Histologic Specimen From Benign and Malignant Breast Lesions. <b>2020</b> , 51, 1868-1878	7
497	Advancing the Science of Cancer in Latinos. <b>2020</b> ,	2
496	Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results. <b>2020</b> , 49, 101-107	8
495	The changing role of pathologists from morphologists to molecular pathologists in the era of precision medicine. <b>2020</b> , 26, 27-34	1
494	Prospective study of a diabetes risk reduction diet and the risk of breast cancer. <b>2020</b> , 112, 1492-1503	12
493	The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment. <b>2020</b> , 29, 2463-2474	5
492	Advances in the Molecular Taxonomy of Breast Cancer. <b>2020</b> , 51, 777-783	7
491	Understanding of tumourigenesis in canine mammary tumours based on cancer stem cell research. <b>2020</b> , 265, 105560	0
490	Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer. <b>2020</b> , 183, 525-547	5
489	Comparison between surgery plus radiotherapy and radiotherapy alone in treating breast cancer patients with ipsilateral supraclavicular lymph node metastasis. <b>2020</b> , 9, 1513-1520	0
488	Feline Mammary Carcinoma: Past, Present and Future. <b>2020</b> , 419-435	
487	An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier. <b>2020</b> , 12,	3
486	Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer. <b>2020</b> , 21,	9
485	Prediction of the clinicopathological subtypes of breast cancer using a fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI. <b>2020</b> , 20, 1073	5
484	Multiparametric MRI-based radiomics analysis for the prediction of breast tumor regression patterns after neoadjuvant chemotherapy. <b>2020</b> , 13, 100831	10
483	Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. <b>2020</b> , 126, 4847-4858	15
482	Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients. <b>2020</b> , 12, 771-781	1
481	Triple-negative pleomorphic lobular carcinoma and expression of androgen receptor: Personal case series and review of the literature. <b>2020</b> , 15, e0235790	2

480	Phospho-Ser-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer. <b>2020</b> , 31, 107745	4
479	Expression of Ki67 and p53 Proteins: Breast Cancer Aggressivity Markers in Brazilian Young Patients. <b>2021</b> , 10, 379-388	0
478	MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. <b>2020</b> , 5, e000937	4
477	A Bioinformatic Pipeline Places STAT5A as a miR-650 Target in Poorly Differentiated Aggressive Breast Cancer. <b>2020</b> , 21,	
476	Iodine-131 labeled genistein as a potential radiotracer for breast cancer. <b>2020</b> , 6, e04780	2
475	Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. <b>2020</b> , 184, 311-324	6
474	Breast Cancer Subtypes Underlying EMT-Mediated Catabolic Metabolism. <b>2020</b> , 9,	5
473	Gelatin Electrospun Mat as a Potential Co-culture System for Production of Sperm Cells from Embryonic Stem Cells. <b>2020</b> , 6, 5823-5832	2
472	TILs Immunophenotype in Breast Cancer Predicts Local Failure and Overall Survival: Analysis in a Large Radiotherapy Trial with Long-Term Follow-Up. <b>2020</b> , 12,	5
471	Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. <b>2020</b> , 21,	7
470	A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study. <b>2020</b> , 60, 232-235	1
469	High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision. <b>2020</b> , 216, 153283	1
468	Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types. <b>2020</b> , 33, 1753-1763	10
467	Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects.. <b>2020</b> , 1, 518-532	7
466	Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape. <b>2020</b> , 12,	1
465	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. <b>2020</b> , 477, 545-555	2
464	Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. <b>2020</b> , 25, e1481-e1491	27
463	Magnetic resonance imaging features for predicting axillary lymph node metastasis in patients with breast cancer. <b>2020</b> , 129, 109093	7

462	E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. <b>2020</b> , 33, 2483-2498	7
461	Comparison between AJCC 8th prognostic stage and UICC anatomical stage in patients with primary breast cancer: a single institutional retrospective study. <b>2020</b> , 27, 1114-1125	
460	Metabolic and OXPHOS Activities Quantified by Temporal Analysis Display Patient-Specific Metabolic Vulnerabilities in Human Breast Cancers. <b>2020</b> , 10, 1053	1
459	Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype. <b>2020</b> , 43, 362-371	0
458	Utility of F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging for Prediction of Metastasis to Sentinel and Nonsentinel Nodes in Patients with Clinically Node-Negative Breast Cancer. <b>2020</b> , 27, 2698-2710	0
457	Correlation of Insulin-like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast Cancer in the UAE. <b>2020</b> , 40, 1555-1561	0
456	Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer. <b>2020</b> , 27, 819-827	5
455	Differentiation between Luminal A and B Molecular Subtypes of Breast Cancer Using Pharmacokinetic Quantitative Parameters with Histogram and Texture Features on Preoperative Dynamic Contrast-Enhanced Magnetic Resonance Imaging. <b>2020</b> , 27, e35-e44	8
454	Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer. <b>2020</b> , 20, 598	7
453	Performance analysis of the anti-Ki67 antibody clone 30-9 for immunohistochemical staining of breast cancer. <b>2020</b> , 27, 1058-1064	2
452	Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. <b>2020</b> , 10, 1023	14
451	Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis. <b>2020</b> , 11, 218-239	5
450	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <b>2020</b> , 136, 43-51	3
449	Double Agent: Gene with Both Oncogenic and Tumor-Suppressor Functions in Breast Cancer. <b>2020</b> , 12, 3891-3902	2
448	Automated assessment of Ki-67 in breast cancer: the utility of digital image analysis using virtual triple staining and whole slide imaging. <b>2020</b> , 77, 471-480	6
447	Invasive breast cancer: Current perspectives and emerging views. <b>2020</b> , 70, 242-252	8
446	Predicting Stage-Specific Recurrent Aberrations From Somatic Copy Number Dataset. <b>2020</b> , 11, 160	1
445	Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. <b>2020</b> , 22, 1364-1377	

444	Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients. <b>2020</b> , 20, 249-259	11
443	The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. <b>2020</b> , 10, 225	38
442	MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes. <b>2020</b> , 180, 73-86	8
441	Failure of sentinel lymph node mapping in breast cancer patients qualified for treatment sparing axillary lymph nodes-Clinical importance and management strategy-One-center analysis. <b>2020</b> , 26, 873-881	3
440	ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer. <b>2020</b> , 21,	10
439	Optimal acquisition time to discriminate between breast cancer subtypes with contrast-enhanced cone-beam CT. <b>2020</b> , 101, 391-399	3
438	Review of the current state of digital image analysis in breast pathology. <b>2020</b> , 26, 1208-1212	2
437	Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. <b>2020</b> , 51, 120-126	10
436	Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups. <b>2020</b> , 20, 253-261.e7	3
435	Identification of Luminal Subtypes of Breast Carcinoma Using Surrogate Immunohistochemical Markers and Ascertaining Their Prognostic Relevance. <b>2020</b> , 20, 382-389	3
434	The effect of smoking on biological change of recurrent breast cancer. <b>2020</b> , 18, 153	2
433	Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. <b>2021</b> , 61, 461-471	5
432	Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer. <b>2021</b> , 5, pkaa087	3
431	Alternative volumetric PET pmirometers for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis. <b>2021</b> , 65, 38-45	2
430	Metabolism and immunity in breast cancer. <b>2021</b> , 15, 178-207	5
429	A Novel Neoplastic Fusion Transcript, , Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers. <b>2021</b> , 27, 785-798	3
428	Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes. <b>2021</b> , 500, 64-74	2
427	Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis. <b>2021</b> , 142, 63-82	7



426	Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review. <b>2021</b> , 99, 613-637	15
425	Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival. <b>2021</b> , 28, 307-320	2
424	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. <b>2021</b> , 185, 557-566	5
423	Protein co-expression networks identified from HOT lesions of ER+HER2-Ki-67high luminal breast carcinomas. <b>2021</b> , 11, 1705	0
422	Research Progress on FOXF2 Gene in Tumors. <b>2021</b> , 11, 763-772	
421	Current Biomarkers for Precision Medicine in Breast Cancer. <b>2021</b> , 1187, 363-379	1
420	Triphasic DeepBRCA-A Deep Learning-Based Framework for Identification of Biomarkers for Breast Cancer Stratification. <b>2021</b> , 9, 103347-103364	0
419	Getting a Grip on Ki-67. <b>2021</b> , 29, 83-85	2
418	Rare common bile duct metastasis of breast cancer: A case report and literature review. <b>2021</b> , 13, 147-156	1
417	Advanced Approaches to Breast Cancer Classification and Diagnosis. <b>2020</b> , 11, 632079	15
416	Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer. <b>2021</b> , 304, 783-790	0
415	DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis. <b>2021</b> , 187, 57-67	2
414	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <b>2021</b> , 23, 21	4
413	Alternative splicing of ceramide synthase 2 alters levels of specific ceramides and modulates cancer cell proliferation and migration in Luminal B breast cancer subtype. <b>2021</b> , 12, 171	5
412	Genomic Assays in Node Positive Breast Cancer Patients: A Review. <b>2020</b> , 10, 609100	5
411	Predicción del resultado del test Oncotype DX con RM mamaria de 1.5T en tumores con receptores hormonales positivos y HER2 negativo. <b>2021</b> , 34, 185-185	
410	Experimental Breast Cancer Models: Preclinical Imaging Perspective. <b>2021</b> , 14, 5-14	0
409	Clinical significance of changes in the expression level of markers of surrogate breast cancer subtypes in recurrent and metastatic foci (literature review). <b>2021</b> , 16, 41-45	

408	High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. <b>2021</b> , 23, 40	3
407	Sous-types moléculaires de cancers du sein : quels enjeux pour faire évoluer le dépistage en France. <b>2021</b> , 31, 6-12	
406	Advances in biofabrication techniques for collagen-based 3D in vitro culture models for breast cancer research. <b>2021</b> , 122, 111944	7
405	Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients. <b>2021</b> , 147, 1937-1955	2
404	Nomograms for Predicting Axillary Lymph Node Status Reconciled With Preoperative Breast Ultrasound Images. <b>2021</b> , 11, 567648	0
403	An analysis of Ki-67 expression in stage 1 invasive ductal breast carcinoma using apparent diffusion coefficient histograms. <b>2021</b> , 11, 1518-1531	9
402	Genetic platforms: Do we do what we know? or do we know what we do?. <b>2021</b> , 34, 100-110	
401	Expression of CCL2/CCR2 signaling proteins in breast carcinoma cells is associated with invasive progression. <b>2021</b> , 11, 8708	3
400	The role of microRNAs on doxorubicin drug resistance in breast cancer. <b>2021</b> , 73, 997-1006	3
399	Differentiation and Regulation of T Cells: A Balancing Act for Cancer Immunotherapy. <b>2021</b> , 12, 669474	16
398	Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations. <b>2021</b> , 1	0
397	Intravoxel incoherent motion magnetic resonance imaging for breast cancer: A comparison with molecular subtypes and histological grades. <b>2021</b> , 78, 35-41	2
396	Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma. <b>2021</b> , 17, 197	0
395	Expression of thrombospondin-1 in conjunctival squamous cell carcinoma is correlated to the Ki67 index and associated with progression-free survival. <b>2021</b> , 259, 3127-3136	1
394	Intratumoral and Peritumoral Radiomics Based on Functional Parametric Maps from Breast DCE-MRI for Prediction of HER-2 and Ki-67 Status. <b>2021</b> , 54, 703-714	6
393	Predictive Role of Leptin Receptor (Ob-R) Overexpression in Patients with Early Breast Cancer Receiving Neoadjuvant Systemic Treatment. <b>2021</b> , 13,	1
392	Sugar-Sweetened Beverages, Artificially Sweetened Beverages, and Breast Cancer Risk: Results From 2 Prospective US Cohorts. <b>2021</b> , 151, 2768-2779	2
391	Osmotic pressure modulates single cell cycle dynamics inducing reversible growth arrest and reactivation of human metastatic cells. <b>2021</b> , 11, 13455	3

390	Evaluation of molecular markers GSTM1 and GSTT1 and clinical factors in breast cancer: case-control study and literature review. <b>2021</b> , 51, 1326-1334	0
389	Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. <b>2021</b> , 81, 654-665	3
388	Breast cancer: Muscarinic receptors as new targets for tumor therapy. <b>2021</b> , 12, 404-428	1
387	The Multifaceted Functions of Autophagy in Breast Cancer Development and Treatment. <b>2021</b> , 10,	9
386	Peritumoral edema in breast cancer at preoperative MRI: an interpretative study with histopathological review toward understanding tumor microenvironment. <b>2021</b> , 11, 12992	1
385	Invasive lobular carcinoma: clinicopathological features and subtypes. <b>2021</b> , 49, 3000605211017039	0
384	Valproic Acid and Breast Cancer: State of the Art in 2021. <b>2021</b> , 13,	6
383	Hedgehog gene expression patterns among intrinsic subtypes of breast cancer: Prognostic relevance. <b>2021</b> , 223, 153478	0
382	Correlation between ER, PR, HER-2, and Ki-67 with the risk of bone metastases detected by bone scintigraphy in breast cancer patients: A cross sectional study. <b>2021</b> , 67, 102532	1
381	Accurate prediction of breast cancer survival through coherent voting networks with gene expression profiling. <b>2021</b> , 11, 14645	1
380	Chronological Trends of Breast Ductal Carcinoma In Situ: Clinical, Radiologic, and Pathologic Perspectives. <b>2021</b> , 28, 8699-8709	2
379	Healthful and Unhealthful Plant-Based Diets and Risk of Breast Cancer in U.S. Women: Results from the Nurses' Health Studies. <b>2021</b> , 30, 1921-1931	3
378	Surgical, histological, and immunohistochemical approach to spontaneous malignant mammary tumor in a fancy rat ( <i>Rattus norvegicus domestica</i> ): a case report. <b>2021</b> , 30, 715-719	
377	Expression profiles and functional prediction of long non-coding RNAs LINC01133, ZEB1-AS1 and ABHD11-AS1 in the luminal subtype of breast cancer. <b>2021</b> , 19, 364	2
376	Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. <b>2021</b> , 13,	49
375	A CROSS SECTIONAL STUDY OF BREAST CANCER HISTOMORPHOLOGY AND ITS CORRELATION WITH ER/PR, HER 2NEU AND KI-67 EXPRESSION IN A TERTIARY CARE HOSPITAL AT KANPUR. <b>2021</b> , 9-12	0
374	Human Epidermal Growth Factor Receptor Type 2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes. <b>2021</b> ,	1
373	Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level. <b>2021</b> , 21, 918	0

372	PI3K/AKT and MAPK1 molecular changes preceding matrix metalloproteinases overexpression during tamoxifen-resistance development are correlated to poor prognosis in breast cancer patients. <b>2021</b> , 28, 1358-1366	3
371	Prediction of breast cancer molecular subtypes using DCE-MRI based on CNNs combined with ensemble learning. <b>2021</b> , 66,	3
370	Binacox: automatic cut-point detection in high-dimensional Cox model with applications in genetics. <b>2021</b> ,	
369	Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. <b>2021</b> , 13,	9
368	Vorinostat (SAHA) and Breast Cancer: An Overview. <b>2021</b> , 13,	7
367	Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method. <b>2021</b> , 11, 737781	4
366	Subtypes of luminal breast carcinoma according to the Saint Gallen Consensus in a group of Venezuelan patients. <b>2021</b> , 41, 531-540	
365	Reproducibility of mRNA-Based Testing of , , and Expression in Invasive Breast Cancer-A Europe-Wide External Quality Assessment. <b>2021</b> , 13,	1
364	Clinicopathological analysis of invasive cribriform carcinoma of the breast, with review of the literature. <b>2021</b> , 54, 151794	0
363	Models for Predicting Sentinel and Non-sentinel Lymph Nodes Based on Pre-operative Ultrasonic Breast Imaging to Optimize Axillary Strategies. <b>2021</b> , 47, 3101-3110	1
362	Adipose-derived stem/stromal cell secretome modulates breast cancer cell proliferation and differentiation state towards aggressiveness. <b>2021</b> , 191, 69-77	0
361	Post-Operative Complications and Nipple Necrosis Rates Between Conventional and Robotic Nipple-Sparing Mastectomy. <b>2020</b> , 10, 594388	6
360	Immunoexpression of claudin-4 and correlation with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-neu in breast cancer. <b>2021</b> ,	
359	ID1 and ID4 Are Biomarkers of Tumor Aggressiveness and Poor Outcome in Immunophenotypes of Breast Cancer. <b>2021</b> , 13,	1
358	Treatment of NETs from Rare Origin. <b>2021</b> , 211-229	
357	Prognostic significance of TRIM28 expression in patients with breast carcinoma. <b>2021</b> , 16, 472-480	0
356	Histopathological and Immunohistochemical Classification of Invasive Breast Carcinomas. <b>2019</b> , 237-247	1
355	Breast Cancer Risk and Mortality in Women of Latin American Origin. <b>2020</b> , 45-55	2

354	Canine and Feline Spontaneous Mammary Tumours as Models of Human Breast Cancer. <b>2020</b> , 173-207	2
353	Automatic Determination of Hormone Receptor Status in Breast Cancer Using Thermography. <b>2016</b> , 636-643	1
352	Pathology of BRCA Tumors. <b>2017</b> , 89-117	1
351	Metronomic Chemotherapy in Breast Cancers. <b>2014</b> , 93-110	1
350	Immunohistochemistry and Molecular Biology of Breast Cancers: Old and New Prognostic Factors. <b>2011</b> , 119-148	3
349	Breast. <b>2011</b> , 1659-1770	5
348	Predictive and Prognostic Marker Testing in Breast Pathology: Immunophenotypic Subclasses of Disease. <b>2012</b> , 151-172	1
347	Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. <b>2021</b> , 3, 12-24	18
346	Photoacoustic imaging of breast cancer: a mini review of system design and image features. <b>2019</b> , 24, 1-13	36
345	Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer. <b>2019</b> , 2019, 7386734	8
344	Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. <b>2018</b> , 128, 5603-5619	26
343	Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma. <b>2015</b> , 21, 2943-9	4
342	Decreased Wnt5a Expression is a Poor Prognostic Factor in Triple-Negative Breast Cancer. <b>2016</b> , 22, 1-7	18
341	Quantitative and Qualitative Evaluation of Breast Cancer Prognosis: A Sonographic Elastography Study. <b>2019</b> , 25, 9272-9279	5
340	Altered expression of insulin receptor isoforms in breast cancer. <b>2011</b> , 6, e26177	44
339	Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival. <b>2012</b> , 7, e30992	68
338	Generation and analysis of a mouse intestinal metatranscriptome through Illumina based RNA-sequencing. <b>2012</b> , 7, e36009	49
337	Stromal genes add prognostic information to proliferation and histoclinical markers: a basis for the next generation of breast cancer gene signatures. <b>2012</b> , 7, e37646	15

336	Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay. <b>2013</b> , 8, e66573	6
335	Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). <b>2013</b> , 8, e70634	13
334	Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. <b>2013</b> , 8, e72053	30
333	Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer. <b>2013</b> , 8, e76379	51
332	High levels of BCOX1 expression are associated with poor prognosis in patients with invasive ductal carcinomas of the breast. <b>2014</b> , 9, e86952	8
331	Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. <b>2014</b> , 9, e91407	11
330	Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. <b>2014</b> , 9, e95629	25
329	The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells. <b>2014</b> , 9, e97697	31
328	Prognostic value of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in breast cancer. <b>2014</b> , 9, e99528	20
327	Absence of gamma-interferon-inducible lysosomal thiol reductase (GILT) is associated with poor disease-free survival in breast cancer patients. <b>2014</b> , 9, e109449	15
326	Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study. <b>2015</b> , 10, e0119565	46
325	An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer. <b>2015</b> , 10, e0125131	34
324	Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers. <b>2016</b> , 11, e0151054	8
323	Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers. <b>2016</b> , 11, e0158259	12
322	Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRI. <b>2016</b> , 11, e0159949	20
321	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. <b>2016</b> , 11, e0164013	4
320	Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. <b>2017</b> , 12, e0168669	75
319	Protein expression patterns of cell cycle regulators in operable breast cancer. <b>2017</b> , 12, e0180489	12

318	Magnetic resonance imaging and pathological characteristics of pure mucinous carcinoma in the breast according to echogenicity on ultrasonography. <b>2017</b> , 36, 131-138	3
317	Predictors of Positive or Close Surgical Margins in Breast-Conserving Surgery for Patients with Breast Cancer. <b>2018</b> , 6, 11-19	3
316	Competing risks in low-risk breast cancer. <b>2013</b> , 32-9	2
315	[Modern pathologic diagnostics in breast cancer]. <b>2012</b> , 153, 22-30	3
314	Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT. <b>2020</b> , 66, 673-679	2
313	[Epithelial cadherins and associated molecules in invasive lobular breast cancer]. <b>2017</b> , 79, 12-18	5
312	[Comparison of digital and visual methods for Ki-67 assessment in invasive breast carcinomas]. <b>2018</b> , 80, 38-42	3
311	Pyridoxine 5'-phosphate oxidase is correlated with human breast invasive ductal carcinoma development. <b>2019</b> , 11, 2151-2176	14
310	Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. <b>2014</b> , 1, 709-24	28
309	DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer. <b>2017</b> , 8, 62834-62841	11
308	Identification of breast cancer cell subtypes sensitive to ATG4B inhibition. <b>2016</b> , 7, 66970-66988	42
307	Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer. <b>2016</b> , 7, 85798-85812	11
306	Unique epigenetic gene profiles define human breast cancers with poor prognosis. <b>2016</b> , 7, 85819-85831	7
305	Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer. <b>2017</b> , 8, 9794-9805	19
304	CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer. <b>2017</b> , 8, 15789-15801	25
303	Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. <b>2017</b> , 8, 26122-26128	14
302	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. <b>2017</b> , 8, 21733-21740	13
301	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <b>2017</b> , 8, 21930-21937	10

300	Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. <b>2017</b> , 8, 37172-37185	4
299	Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes. <b>2017</b> , 8, 42917-42925	6
298	Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers. <b>2017</b> , 8, 63405-63416	8
297	High Eg5 expression predicts poor prognosis in breast cancer. <b>2017</b> , 8, 62208-62216	20
296	Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes. <b>2017</b> , 8, 63963-63970	26
295	Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer. <b>2018</b> , 9, 2697-2704	17
294	Reduced expression of $\alpha$ -Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients. <b>2018</b> , 9, 15228-15238	5
293	Identification of copy number alterations in colon cancer from analysis of amplicon-based next generation sequencing data. <b>2018</b> , 9, 20409-20425	5
292	Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling. <b>2018</b> , 9, 33348-33359	8
291	Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity. <b>2019</b> , 10, 198-208	18
290	Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. <b>2015</b> , 6, 23944-58	15
289	Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors. <b>2015</b> , 6, 34892-909	12
288	Klotho is a novel marker and cell survival factor in a subset of triple negative breast cancers. <b>2016</b> , 7, 2611-28	8
287	Differentiation between genetic mutations of breast cancer by breath volatolomics. <b>2015</b> , 6, 44864-76	44
286	Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. <b>2016</b> , 7, 17314-26	22
285	Tumor suppressor berberine binds VASP to inhibit cell migration in basal-like breast cancer. <b>2016</b> , 7, 45849-45862	27
284	Rare epithelial breast cancer: surgery and adjuvant therapy.. <b>2019</b> , 8, S479-S492	1
283	Relation of peritumoral, prepectoral and diffuse edema with histopathologic findings of breast cancer in preoperative 3T magnetic resonance imaging.	2



282	Iterative integrated imputation for missing data and pathway models with applications to breast cancer subtypes. <b>2019</b> , 26, 411-430	2
281	Histological and molecular classification of breast cancer: what do we know?. 30,	9
280	Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas. <b>2019</b> , 20, 73-79	15
279	Luminal B is the Most Common Intrinsic Molecular Subtypes of Invasive Ductal Breast Carcinoma Patients in East Kalimantan, Indonesia. <b>2019</b> , 20, 2247-2252	1
278	Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer. <b>2019</b> , 17, eAO3434	4
277	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <b>2016</b> , 20, xxiii-xxix, 1-201	42
276	Correlation of the Strain Elastography-Derived Elasticity Scores with Prognostic Histologic Features, Immunohistochemical Markers, and Molecular Subtypes of Invasive Ductal Carcinoma. <b>2019</b> , 80, 717	2
275	Keratinocyte growth factor gene therapy ameliorates ulcerative colitis in rats. <b>2011</b> , 17, 2632-40	13
274	Identification of candidate RNA signatures in triple-negative breast cancer by the construction of a competing endogenous RNA network with integrative analyses of Gene Expression Omnibus and The Cancer Genome Atlas data. <b>2020</b> , 19, 1915-1927	4
273	Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal-type breast cancer. <b>2020</b> , 20, 193	4
272	Evaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?. <b>2014</b> , 6, 785-94	5
271	Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients. <b>2020</b> , 23, 182-193	4
270	Impact of St. Gallen surrogate classification for intrinsic breast cancer sub-types on disease features, recurrence, and survival in South Indian patients. <b>2020</b> , 57, 49-54	6
269	Predicting the molecular subtype of breast cancer based on mammography and ultrasound findings. <b>2018</b> , 28, 354-361	21
268	Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling. <b>2018</b> , 7, 96-101	4
267	Interobserver Variability of Ki-67 Measurement in Breast Cancer. <b>2016</b> , 50, 129-37	14
266	Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer. <b>2020</b> , 54, 87-94	5
265	Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes. <b>2017</b> , 49, 484-493	9

264	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. <b>2017</b> , 49, 454-463	1
263	Standardized Assessment of Ki-67 in Breast Cancer Patients Using Virtual Slides and an Automated Analyzer in Comparison to Central/Local Pathological Assessments. <b>2014</b> , 05, 141-146	3
262	Comparing Oncotype DX Recurrence Score Categories with Immunohistochemically Defined Luminal Subtypes. <b>2016</b> , 07, 223-231	1
261	Immunohistochemical Biomarkers in Ductal Carcinoma & In Situ. <b>2020</b> , 10, 129-146	1
260	Biological subtypes of breast cancer: Prognostic and therapeutic implications. <b>2014</b> , 5, 412-24	390
259	Additional Value of Diffusion-Weighted Imaging to Evaluate Prognostic Factors of Breast Cancer: Correlation with the Apparent Diffusion Coefficient. <b>2016</b> , 13, e33133	20
258	Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ. <b>2013</b> , 68, 638-43	11
257	Survival time and molecular subtypes of breast cancer after radiotherapy in Thailand. <b>2014</b> , 15, 10505-8	9
256	Molecular Profiling of Breast Carcinoma in Almadinah, KSA: Immunophenotyping and Clinicopathological Correlation. <b>2015</b> , 16, 7819-24	7
255	Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer. <b>2015</b> , 16, 8397-403	5
254	Roles of Ki67 in Breast Cancer - Important for Management?. <b>2016</b> , 17, 1077-82	4
253	Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki-67 in Chinese breast cancer patients: A retrospective study of 525 patients. <b>2017</b> ,	6
252	A DNA Methylation-Based Gene Signature Can Predict Triple-Negative Breast Cancer Diagnosis. <b>2021</b> , 9,	
251	Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. <b>2021</b> ,	3
250	Evolution of HER2-low expression from primary to recurrent breast cancer. <b>2021</b> , 7, 137	4
249	Tratamiento del c�ncer de mama infiltrante localizado: nuevos desaf�os. <b>2021</b> , 57, 1-20	
248	Will preoperative trials change future clinical practice?. <b>2011</b> , 1, 59-73	1
247	A CLINICOPATHOLOGICAL STUDY OF 32 CASES OF APOCRINE CARCINOMA OF THE BREAST. <b>2012</b> , 58, 311-318	

246 Comment dfinir un cancer infiltrant de pronostic intermdiaire?. **2012**, 137-142

245 Pas de chimiothrapie pour quels cancers infiltrants Moins de « facteurs pronostiques » et plus de biologie?. **2012**, 121-124

244 Molecular Classification of Breast Carcinoma. **2012**, 365-379

243 Surveillance, ^la recherche des mfastases : trop ou pas assez?. **2012**, 174-177

242 Molecular Classification. **2013**, 21-34

241 Dfinition biologique de l'agressivit'tumorale : les signatures biologiques peuvent-elles tre utilisès en pratique clinique ?. **2013**, 72-78

240 The effect of biology in the treatment of small breast tumors. **2013**, 25-31

239 The role of adjuvant systemic therapy in patients with operable breast cancer. **2014**, 199-218

238 Molecular Testing in Breast Cancer. **2014**, 169-188

237 Profil molculaire du cancer du sein : expfience du CHU Mohammed VI Marrakech. fr1,

236 Auto-Analysis for Ki-67 Indices of Breast Cancer Using Specified Computer Software and a Virtual Microscopy. **2014**, 3, 88-93

235 Molecular Medicine and Personalized Therapy for Breast Cancer Patients. **2015**, 321-334

234 Early Biomarkers in Breast Cancer. **2015**, 61-142

233 Role of Genetic Profiling and Recurrence Scores in Treatment Planning for DCIS. **2015**, 109-115

232 Alterations of Biomarkers by Neoadjuvant Endocrine Therapy. **2016**, 217-231

231 Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers. **2016**, 75, 10-15

230 Aromatase Inhibitors for Breast Cancer Prevention. **2016**, 103-111

1

229 Clinical Applications for Immunohistochemistry of Breast Lesions. **2016**, 1406, 11-37

- 228 Evaluation of Patients for Metastases Prior to Primary Therapy. **2016**, 13-24
- 227 Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. **2016**, 803-817
- 226 Breast Cancer Molecular Subtypes Among Moroccan Women. **2016**, 3, 47-54
- 225 Expression Profiling, Protein. **2016**, 486-493
- 224 Expression Profiling, mRNA. **2016**, 474-477
- 223 Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type). **2016**, 238-247
- 222 Adjuvant Systemic Chemotherapy for HER2-Negative Disease. **2016**, 131-187
- 221 Gene Expression Analysis: Applications. **2016**, 137-149
- 220 Molecular Classification of Breast Cancer. **2016**, 203-219 ○
- 219 Molecular Classification of Breast Cancer. **2017**, 1-22
- 218 Correlation between contrast-enhanced ultrasound findings and clinicopathological factors in breast cancer. **2017**, 44, 41-48
- 217 Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy. **2017**, 29, 369-373 ○
- 216 Zukünftige Entwicklungen in der Bildgebung. **2017**, 201-218
- 215 The prognostic effects of somatic mutations in ER-positive breast cancer.
- 214 Automated digital image analysis and manual counting of Ki-67 proliferation index in patients with breast cancer. **2017**, 37, 228-235
- 213 The reliability of assessment of Ki-67 and HER-2/neu expression on breast carcinoma agarose cell blocks. **2017**, 37, 221-227 1
- 212 Stochastic Geometry for Automatic Assessment of Ki-67 Index in Breast Cancer Preparations. **2018**, 151-162
- 211 Favorable Reproducibility of Ki-67-Labeling Index between Core Needle Biopsy and Surgical Materials in Mammary Carcinoma: Reproducibility Influenced by Hot Spots, a High Ki-67 Labeling Index, and the Total Length of Biopsy Material. **2018**, 08, 647-659

210	Basic Molecular Pathology in Breast Carcinoma. <b>2018</b> , 357-372	0
209	Association of high proliferation marker Ki-67 expression with DCEMR imaging features of breast: a large scale evaluation. <b>2018</b> ,	
208	Assessment of Ki-67 for Predicting Effective Prognosis in Breast Cancer Subtypes. <b>2018</b> , 24, 9-14	3
207	Prognostic and Predictive Factors. <b>2019</b> , 171-186	
206	Use of positron emission tomography-computed tomography to predict axillary metastasis in patients with triple-negative breast cancer. <b>2018</b> , 14, 135-141	1
205	Identifying breast cancer patients who require a double-check of preoperative core needle biopsy and postoperative surgical specimens to determine the molecular subtype of their tumor. <b>2019</b> , 97, 223-229	0
204	Staging and Prognostic Factors. <b>2019</b> , 249-259	
203	Evaluation of Patients for Metastases Prior to Primary Therapy. <b>2019</b> , 11-23	
202	Progression free survival in Iraqi breast cancer patients treated with adjuvant 3D conformal radiotherapy: A cross-sectional study. 8, 71	1
201	Ki-67, an elusive marker in the prognosis of breast cancer. <b>2019</b> , 150, 214-216	1
200	Adjuvant Systemic Chemotherapy for HER2-Negative Disease. <b>2019</b> , 129-171	
199	Prognostic and Predictive Factors. <b>2019</b> , 163-172	
198	The modern trends in diagnosis and treatment of primary operable breast cancer. <b>2019</b> , 14, 24-34	3
197	Dimensional Analysis of CD44 CD24 and Ki67 in Triple Negative Breast Cancer. <b>2019</b> , 7, 526-528	1
196	Treatment Outcomes of Weakly Positive Hormone Receptor Breast Cancer and Triple-Negative Breast Cancer. <b>2019</b> , 7, 1-8	2
195	Molecular Characterisation of Carcinoma Breast Using Surrogate IHC Markers-ER/PR, HER-2, CK5/6, EGFR, Ki-67. <b>2019</b> , 8, 3464-3468	
194	Prediction of the clinicopathological subtypes of breast cancer using a Fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI.	
193	Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer. <b>2020</b> , 22, 2275-2285	0

- 192 Personalized analysis of breast cancer using sample-specific networks. **2020**, 8, e9161 2
- 191 Anticancer bioactive peptide combined with docetaxel and its mechanism in the treatment of breast cancer. **2020**, 20, 1917-1924 1
- 190 The Analysis of the effect of ER, PR, HER-2 and Ki-67 index on the number of metastasized axillary lymph node in breast cancer. **2020**, 5, 75-78
- 189 Pathological Aspects for Diagnosis. **2022**, 47-67
- 188 Characterization of the Relationship Between the Expression of Aspartate  $\beta$ -Hydroxylase and the Pathological Characteristics of Breast Cancer. **2020**, 26, e926752 2
- 187 Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients. **2021**, 32, 251-260 4
- 186 Empfehlungen der Österreichischen Gesellschaft für Senologie (Nachsorge nach Mammakarzinom). **2020**, 17, 232-235
- 185 A negative binomial regression model for risk estimation of 0-2 axillary lymph node metastases in breast cancer patients. **2020**, 10, 21856 1
- 184 Digital Breast Tomosynthesis as a Breast Cancer Screening Tool for Women with Gynecologic Cancer. **2020**, 81, 886
- 183 Ki-67 in breast cancer:. **2020**, 57, 231-233
- 182 Surrogate molecular classification of breast carcinoma: A classification in need or a dilemma indeed. **2020**, 4, 79
- 181 Evaluation of non-coding region sequence variants and mitochondrial haplogroups as potential biomarkers of sporadic breast cancer in individuals of Sri Lankan Sinhalese ethnicity. **2020**, 12, 339-347 1
- 180 Biological rationale for patient-specific treatment of breast cancer. Analysis of new data for breast cancer. **2020**, 15, 30-49 1
- 179 Hormone Receptor-status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape.
- 178 Immunohistochemical profile of cytokeratins (5, 7, 14, 18, 20) in retrospective cases of breast fibroadenomas. **2020**, 5, 035-043 1
- 177 Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross-Sectional Study in Vietnam. **2020**, 21, 1135-1142 0
- 176 Can Estrogen Receptor, Progesterone Receptor, and Proliferative Index be Considered as Isolated Prognostic Factors of Overall Survival in Early luminal Breast Cancer?. **2020**, 9, 1313-1322
- 175 Wound-like tumor periphery in human breast cancer predicts a convergent drug nonresponse. 0

174	Prädiktive und prognostische Faktoren in der Therapie des frühen Mammakarzinoms. <b>2021</b> , 27, 1175	
173	Accurate Prediction of Breast Cancer Survival through Coherent Voting Networks with Gene Expression Profiling.	
172	Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer. <b>2013</b> , 25, 397-404	3
171	The breast. 571-687	1
170	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. <b>2010</b> , 4, 35-41	389
169	Invasive cribriform carcinoma in a Chinese population: comparison with low-grade invasive ductal carcinoma-not otherwise specified. <b>2013</b> , 6, 445-57	12
168	[Molecular classification of breast cancer in Morocco]. <b>2012</b> , 13, 91	6
167	Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population. <b>2014</b> , 7, 3202-12	4
166	How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?. <b>2012</b> , 1, 156-8	
165	Male breast carcinoma: a clinicopathological and immunohistochemical characterization study. <b>2014</b> , 7, 6852-61	6
164	Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer. <b>2015</b> , 5, 375-85	11
163	Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients. <b>2015</b> , 8, 7059-71	10
162	Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine. <b>2015</b> , 5, 2330-43	17
161	Inhibitory effects of O-methylated isoflavone glycitein on human breast cancer SKBR-3 cells. <b>2015</b> , 8, 7809-17	3
160	Expression of alpha B crystallin and BCL2 in patients with infiltrating ductal carcinoma. <b>2015</b> , 8, 8842-56	6
159	HOXD13 methylation status is a prognostic indicator in breast cancer. <b>2015</b> , 8, 10716-24	13
158	Ki-67 and caspase expression in breast carcinoma: does variance in locational sampling exist?. <b>2015</b> , 8, 11305-13	1
157	Prognostic significance of HOXD13 expression in human breast cancer. <b>2015</b> , 8, 11407-13	6

156	Breast cancer intrinsic subtype classification, clinical use and future trends. <b>2015</b> , 5, 2929-43	296
155	Expression of eag1 channel associated with the aggressive clinicopathological features and subtype of breast cancer. <b>2015</b> , 8, 15093-9	5
154	Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor Size. <b>2018</b> , 19, 161-166	6
153	Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014. <b>2018</b> , 13, 71-77	2
152	Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas. <b>2018</b> , 19, 955-959	4
151	The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman. <b>2018</b> , 19, 1263-1268	4
150	Genomic Testing in the Management of Early-Stage Breast Cancer. <b>2017</b> , 24, 229-238	1
149	Correlation between procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 and breast cancer. <b>2019</b> , 12, 1015-1021	2
148	Prognostic impact of high p16/cyclin D1 index in breast cancer. <b>2019</b> , 12, 2224-2232	1
147	Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study. <b>2020</b> , 82, 457-467	1
146	Molecular alterations differentiate microinvasive carcinoma from ductal carcinoma in situ and invasive breast carcinoma: retrospective analysis of a large single-center series. <b>2021</b> , 14, 892-901	0
145	Clinical and morphological factors associated with two groups of concordant breast cancer immunophenotypes. <b>2021</b> , 9, 197-213	
144	Assessment of Breast Cancer Immunohistochemical Properties with Demographics and Pathological Features; A Retrospective Study. <b>2021</b> , 14,	
143	Diffusion Kurtosis MR Imaging of Invasive Breast Cancer: Correlations With Prognostic Factors and Molecular Subtypes. <b>2021</b> ,	1
142	Compressive stress-mediated p38 activation required for ER $\beta$ phenotype in breast cancer. <b>2021</b> , 12, 6967	1
141	Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram. <b>2021</b> , 11, 718531	2
140	Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. <b>2021</b> , 341, 399-413	3
139	Intratumoral analysis of digital breast tomosynthesis for predicting the Ki-67 level in breast cancer: a multi-center radiomics study. <b>2021</b> ,	0



138	Combination of Neutrophil-to-Lymphocyte Ratio and Red Cell Distribution Width With Serum Tumor Markers for the Differential Diagnosis of Breast Cancer and its Association With Pathological Features and Molecular Types.. <b>2021</b> ,	0
137	Involvement of Par-4 in Breast Cancer. <b>2021</b> , 113-131	
136	Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer.. <b>2022</b> , 14,	2
135	Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy.. <b>2022</b> , 14,	1
134	Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping.. <b>2021</b> , 230, 153750	0
133	Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges. <b>2021</b> , 146, 112488	2
132	Effect of node status on breast cancer survival by subtype: a single-center retrospective cohort study.. <b>2020</b> , 9, 5900-5908	0
131	Nomogram for predicting axillary lymph node status after neoadjuvant chemotherapy in breast cancer.. <b>2020</b> , 9, 7054-7064	0
130	RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts.	
129	Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?. <b>2022</b> , 192, 343	4
128	Impact of intratumoral heterogeneity on the metabolic profiling of breast cancer tissue using high-resolution magic angle spinning magnetic resonance spectroscopy.. <b>2021</b> , e4682	1
127	Oral Contraceptive Use and Breast Cancer Risk According to Molecular Subtypes Status: A Systematic Review and Meta-Analysis of Case-Control Studies.. <b>2022</b> , 14,	0
126	Is Ki67 Effective as a Prognostic Marker in Node-Positive Breast Cancer Patients?. 1	
125	Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management.. <b>2022</b> , 14,	0
124	Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2.. <b>2022</b> , 11, 77-90	0
123	Quantitative Predictors of Response to Neoadjuvant Chemotherapy on Dynamic Contrast-enhanced 3T Breast MRI.	0
122	MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers.. <b>2022</b> , 17, 24	2
121	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.. <b>2022</b> , 13, 896	4

- 120 Update Mammakarzinom 2021 Teil 3 Aktuelle Entwicklungen bei der Behandlung von Brustkrebspatientinnen mit frühen Krankheitsstadien: Übersicht und Beurteilung von speziellen Therapiesituationen durch ein internationales Expertenpanel. **2022**, 19, 75-87 0
- 119 VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.. **2022**,
- 118 Outcomes of Breast-Conserving Surgery Plus Radiation vs Mastectomy for All Subtypes of Early-Stage Breast Cancer: Analysis of More Than 200,000 Women.. **2022**, 234, 450-464 0
- 117 The Role of Copy Number Variants in Gene Co-Expression Patterns for Luminal B Breast Tumors.. **2022**, 13, 806607 0
- 116 Changing the molecular profile of primary and metastatic breast cancer identified by Foundation One: case report. 32,
- 115 Ligand-mediated nanomedicines against breast cancer: a review.. **2022**, 0
- 114 El informe radiológico: informe estructurado, ¿quý cómo? Informe estructurado de RM mama en neoadyuvancia: ¿quinformaciñ se precisa en los comitñ?. **2022**,
- 113 Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients.. **2022**, 2022, 1525245 2
- 112 Data\_Sheet\_1.docx. **2019**,
- 111 Data\_Sheet\_1.docx. **2020**,
- 110 Image\_1.TIF. **2020**,
- 109 Metabolic Syndrome and Breast Cancer Molecular Subtypes: An Observational Patient Study.. **2022**, 16, 11782234221080555 0
- 108 Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer.. **2019**, 5, 72-78 3
- 107 Differences in clinicopathologic features and subtype distribution of invasive breast cancer between women older and younger than 40 years.. **2019**, 5, 92-97 2
- 106 Differences in clinicopathologic features and subtype distribution of invasive breast cancer between elderly and non-elderly women.. **2021**, 7, 59-64
- 105 Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes.. **2021**, 7, 130-135
- 104 Analysis of Breast Cancer Based on the Dysregulated Network.. **2022**, 13, 856075 1
- 103 Assessment of intravoxel incoherent motion MR imaging for differential diagnosis of breast lesions and evaluation of response: a systematic review. **2022**, 53,

102 Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. **2022**, 14, 2404

101 Germline and somatic genetic variability of oxysterol-related genes in breast cancer patients with early disease of the luminal subtype.. **2022**,

100 Identification of a 5-gene-risk score model for predicting luminal A-invasive lobular breast cancer survival.. **2022**, 1

99 Associations between Preserved foods and Breast Cancer Risk in Hong Kong Chinese Women.. **2022**, 1

98 Utility of Personalized Medicine in the Treatment of Different Subtypes of Breast Cancer. **2022**, 337-366

97 AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation. **2022**, 106132

96 ROS1 altered breast cancers a distinctive molecular subtype of PR- metastatic breast cancers: Expanding the scope of targeted therapeutics. **2022**, 41, 295-301

95 EpsteinBarr Virus Association with Breast Cancer: Evidence and Perspectives. **2022**, 11, 799 0

94 Breast. **2022**, 253-292

93 Update on prognostic and predictive biomarkers of breast cancer. **2022**, 0

92 MRI characteristics of breast edema for assessing axillary lymph node burden in early-stage breast cancer: a retrospective bicentric study. 0

91 Expression and prognosis analysis of mitochondrial ribosomal protein family in breast cancer. **2022**, 12, 0

90 Terminal digit preference and the accuracy of breast cancer diameter reporting based on Benford's law. **2022**, 103993

89 Exercise-Induced Circulating microRNAs: Potential Key Factors in the Control of Breast Cancer. 13,

88 Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells. **2022**, 13, 505-519 0

87 Identifying the Best Ki-67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification.

86 Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series.

85 An Innovative Arteriovenous (AV) Loop Breast Cancer Model Tailored for Cancer Research. **2022**, 9, 280 1

84	Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2 <sup>-</sup> Early Breast Cancer Patients. 9,	
83	Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.	1
82	Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. <b>2022</b> , 23, 7079	1
81	Preoperative Evaluation of Non-Mass-Like Enhancement on Magnetic Resonance Imaging for Measuring Tumor Extent and Affecting Surgical Margin Status in Breast Cancer Patients. <b>2022</b> , 10, 29-39	
80	Validation of absolutely quantitated Ki67 and cyclinD1 protein levels for prognosis of Luminal-like breast cancer patients.	0
79	From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. <b>2022</b> , 14, 3469	1
78	Nomograms predicting recurrence in patients with triple negative breast cancer based on ultrasound and clinicopathological features.	
77	Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint. <b>2022</b> , 17,	2
76	The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis. <b>2022</b> , 176, 103757	1
75	The Clonal Relationship Between the Ductal and Lobular Components of Mixed Ductal-Lobular Carcinomas Suggested a Ductal Origin in Most Tumors. Publish Ahead of Print,	
74	Luminal A Breast Cancer: How Feasible is Omitting Axillary Dissection Without Neoadjuvant Therapy. <b>2022</b> , 2022, 1-7	
73	The circulating 70 kDa heat shock protein (HSPA1A) level is a potential biomarker for breast carcinoma and its progression. <b>2022</b> , 12,	0
72	Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.	1
71	High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues.	0
70	Utility of Genomic Platforms in Treatment Decisions in Axilla-Positive Breast Cancer. <b>2022</b> ,	
69	Identification of the lymph node metastasis-related automated breast volume scanning features for predicting axillary lymph node tumor burden of invasive breast cancer via a clinical prediction model. 13,	0
68	Ki67 assessment in invasive luminal breast cancer: A comparative study between different scoring methods.	0
67	A Prospective Multi-Institutional Observational Study on ER, PR, HER2/NEU, and Ki-67 Expression and Discordance Pattern in Primary and Metastatic and Recurrent Carcinoma Breast and Its Therapeutic Implications and Prognostic Outcome.	

66	Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. <b>2022</b> , 349, 844-875	2
65	Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series. Volume 14, 259-280	0
64	Pattern of local recurrence and metastasis in carcinoma breast according to molecular subtype in patients treated with definitive intent. <b>2022</b> , 0	0
63	Prediction of Axillary Lymph Node Metastasis by Combined 5-Immunohistochemistry in Hormone Receptors Positive Breast Cancer.	0
62	Prognostic factors and molecular subtypes in young women with breast cancer. 32,	0
61	Clinical validity and clinical utility of Ki67 in early breast cancer. <b>2022</b> , 14, 175883592211227	2
60	Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement. <b>2022</b> , 12, 1404	1
59	Comparison of Genomic Profiling Data with Clinical Parameters: Implications for Breast Cancer Prognosis. <b>2022</b> , 14, 4197	0
58	Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes in an observational cohort study in Sweden. <b>2022</b> , 22,	1
57	Update Breast Cancer 2022 Part 3 Early-Stage Breast Cancer. <b>2022</b> , 82, 912-921	0
56	A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. 12,	0
55	Molecular Classification of Breast Cancer. <b>2022</b> ,	0
54	Reproductive history differs by molecular subtypes of breast cancer among women aged $\geq 50$ years in Scotland diagnosed 2009-2016: a cross-sectional study.	0
53	Assessment of the relationships between Ki67 expression and neoadjuvant treatment response and prognosis in breast cancer using two types of response evaluation systems.	0
52	Primary neuroendocrine carcinoma of the breast with leptomeninges metastasis: A case report and literature review. <b>2022</b> , 50, 030006052211185	0
51	HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment. 10,	0
50	In situ single-cell analysis of canonical breast cancer biomarkers: phenotypic heterogeneity and implications on response to HER2 targeting agents.	0
49	Single Nucleotide Variants in KIF14 Gene May Have Prognostic Value in Breast Cancer.	0

48	Predicting hormone receptors and PAM50 subtypes of breast cancer from multi-scale lesion images of DCE-MRI with transfer learning technique. <b>2022</b> , 150, 106147	1
47	Expression of MiRNA-29b and MiRNA-31 and their diagnostic and prognostic values in Egyptian females with breast cancer. <b>2022</b> , 7, 248-257	0
46	A genome-wide cell-free DNA methylation analysis identifies an episinature associated with metastatic luminal B breast cancer. 10,	0
45	Metabolomics by NMR Combined with Machine Learning to Predict Neoadjuvant Chemotherapy Response for Breast Cancer. <b>2022</b> , 14, 5055	0
44	Intrinsic subtypes in Ethiopian breast cancer patient. <b>2022</b> , 196, 495-504	0
43	Suppression of vitamin D metabolizing enzyme CYP24A1 provides increased sensitivity to chemotherapeutic drugs in breast cancer.	0
42	Chemopreventive and anti-tumor potential of vitamin E in preclinical breast cancer studies: a systematic review. <b>2022</b> ,	2
41	Impact of intestinal dysbiosis on breast cancer metastasis and progression. 12,	0
40	The Monocyte, a Maestro in the Tumor Microenvironment (TME) of Breast Cancer. <b>2022</b> , 14, 5460	1
39	Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy: A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. <b>2022</b> , 14, 5635	0
38	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. <b>2022</b> , 895-915	0
37	Breast Cancer Pathology in the Era of Genomics. <b>2023</b> , 37, 33-50	0
36	Suppression of CD56bright NK cells in breast cancer patients is associated with the PD-1 and TGF- $\beta$ II expression.	0
35	Preoperative Computed Tomography Radiomics Analysis for Predicting Receptors Status and Ki-67 Levels in Breast Cancer. <b>2022</b> , 45, 526-533	0
34	Radiomics of dynamic contrast-enhanced magnetic resonance imaging parametric maps and apparent diffusion coefficient maps to predict Ki-67 status in breast cancer. 12,	0
33	Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up. <b>2022</b> , 22,	0
32	Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. <b>2022</b> , 13,	1
31	circAR-E2E4-miR-665-STAT3 axis is a potential regulatory network in triple-negative breast cancer. <b>2022</b> , e12654	0

- 30 Long term trends of breast cancer incidence according to proliferation status. **2022**, 22, ○
- 29 AKTIP loss is enriched in ER $\beta$  positive breast cancer for tumorigenesis and confers endocrine resistance. **2022**, 41, 111821 ○
- 28 Translational Results of Zo-NANTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer. **2022**, 23, 15515 ○
- 27 Update Mammakarzinom 2022 Teil 3 Brustkrebs in frühen Krankheitsstadien. **2022**, 19, 365-375 ○
- 26 Prognosis according to the timing of recurrence in breast cancer. **2023**, 104, 1 ○
- 25 An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?. **2023**, 10, 19 ○
- 24 Combination of Conventional Drugs with Biocompounds Derived from Cinnamic Acid: A Promising Option for Breast Cancer Therapy. **2023**, 11, 275 ○
- 23 Establishment and characterization of a HER2-enriched canine mammary cancerous myoepithelial cell line. **2023**, 19, ○
- 22 The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up. ○
- 21 Introduction to Breast Cancer. **2023**, 1-22 ○
- 20 The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies. 14, ○
- 19 Potential cardioprotective and anticancer effects of carvedilol either free or as loaded nanoparticles with or without doxorubicin in solid Ehrlich carcinoma-bearing mice. **2023**, 465, 116448 ○
- 18 CORRELATION BETWEEN PRIMARY TUMOR SIZES WITH PROGNOSTIC MARKERS IN BREAST CARCINOMA IN IRAQI WOMEN: IMMUNOHISTOCHEMICAL STUDY. **2022**, 75, 2771-2778 ○
- 17 Estrogen receptor targeting with genistein radiolabeled Technetium-99m as radiotracer of breast cancer: Its optimization, characterization, and predicting stability constants by DFT calculation. **2023**, 9, e13169 ○
- 16 ABCB1 Amplicon Contains Cyclic AMP Response Element-Driven TRIP6 Gene in Taxane-Resistant MCF-7 Breast Cancer Sublines. **2023**, 14, 296 ○
- 15 Prognostic role of immune environment in luminal B early breast cancer. ○
- 14 Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis. **2023**, 15, 1157 ○
- 13 Using Machine Learning Methods to Assess Lymphovascular Invasion and Survival in Breast Cancer: Performance of Combining Preoperative Clinical and MRI Characteristics. ○

- 12 Expression, assessment and significance of Ki67 expression in breast cancer: an update. *jcp-2022-208731* ○
- 11 Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions. **2023**, 25, 491-500 ○
- 10 Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer. ○
- 9 RANK is a poor prognosis marker and a therapeutic target in ER -negative postmenopausal breast cancer. **2023**, 15, ○
- 8 A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India. ○
- 7 Correlation of androgen receptor with ultrasound, clinicopathological features and clinical outcomes in breast cancer. **2023**, 14, ○
- 6 Adjuvant Dose Dense Chemotherapy in patients with obesity: short-term toxicities and breast cancer outcome. **2023**, ○
- 5 Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications. **2023**, ○
- 4 Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials. ○
- 3 XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes. **2023**, 84, 104979 ○
- 2 Multimodal analysis of genome-wide methylation, copy number aberrations, and end motif signatures enhances detection of early-stage breast cancer. 13, ○
- 1 DNA aneuploidy identifies a subset of Luminal subtype breast carcinoma patients with worse clinical outcome. **2023**, 246, 154513 ○